<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">03385</article-id><article-id pub-id-type="doi">10.7554/eLife.03385</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Differential TAM receptor–ligand–phospholipid interactions delimit differential TAM bioactivities</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-15061"><name><surname>Lew</surname><given-names>Erin D</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-15062"><name><surname>Oh</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-15063"><name><surname>Burrola</surname><given-names>Patrick G</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-15065"><name><surname>Lax</surname><given-names>Irit</given-names></name><xref ref-type="aff" rid="aff2"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-19460"><name><surname>Zagórska</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="par-8"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-18346"><name><surname>Través</surname><given-names>Paqui G</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5749-8426</contrib-id><xref ref-type="aff" rid="aff1"/><xref ref-type="other" rid="par-9"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-19500"><name><surname>Schlessinger</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff2"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-12043"><name><surname>Lemke</surname><given-names>Greg</given-names></name><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf3"/></contrib><aff id="aff1"><institution content-type="dept">Molecular Neurobiology Laboratory</institution>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Department of Pharmacology</institution>, <institution>Yale University School of Medicine</institution>, <addr-line><named-content content-type="city">New Haven</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Immunobiology and Microbial Pathogenesis Laboratory</institution>, <institution>The Salk Institute for Biological Studies</institution>, <addr-line><named-content content-type="city">La Jolla</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goff</surname><given-names>Stephen P</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Columbia University</institution>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>lemke@salk.edu</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>29</day><month>09</month><year>2014</year></pub-date><pub-date pub-type="collection"><year>2014</year></pub-date><volume>3</volume><elocation-id>e03385</elocation-id><history><date date-type="received"><day>15</day><month>05</month><year>2014</year></date><date date-type="accepted"><day>28</day><month>09</month><year>2014</year></date></history><permissions><copyright-statement>© 2014, Lew et al</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Lew et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-03385-v2.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.03385.001</object-id><p>The TAM receptor tyrosine kinases Tyro3, Axl, and Mer regulate key features of cellular physiology, yet the differential activities of the TAM ligands Gas6 and Protein S are poorly understood. We have used biochemical and genetic analyses to delineate the rules for TAM receptor–ligand engagement and find that the TAMs segregate into two groups based on ligand specificity, regulation by phosphatidylserine, and function. Tyro3 and Mer are activated by both ligands but only Gas6 activates Axl. Optimal TAM signaling requires coincident TAM ligand engagement of both its receptor and the phospholipid phosphatidylserine (PtdSer): Gas6 lacking its PtdSer-binding ‘Gla domain’ is significantly weakened as a Tyro3/Mer agonist and is inert as an Axl agonist, even though it binds to Axl with wild-type affinity. In two settings of TAM-dependent homeostatic phagocytosis, Mer plays a predominant role while Axl is dispensable, and activation of Mer by Protein S is sufficient to drive phagocytosis.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.001">http://dx.doi.org/10.7554/eLife.03385.001</ext-link></p></abstract><abstract abstract-type="executive-summary"><object-id pub-id-type="doi">10.7554/eLife.03385.002</object-id><title>eLife digest</title><p>Cells send out and receive signals to communicate with other cells. Detecting these signals is largely carried out by proteins called receptors that span the cell surface membrane. These proteins typically have extracellular domains outside of the cell that can bind to specific signaling molecules and an intracellular domain inside the cell that relays the information inwards to trigger a response.</p><p>Three such receptor proteins are collectively known as the TAM receptors. Each day, many billions of cells in the human body die and are engulfed by other cells and broken down so that their building blocks can be reused. TAM receptors are required for this process; and the TAM receptors also help prevent the immune system from going out of control, which would damage the body's own tissues.</p><p>Two different signaling proteins, called Gas6 and Protein S, can bind to and activate TAM receptors. Both of the signaling proteins can also bind to a phospholipid molecule that is found on the surface membrane of dead cells. However, it is not known if all three TAM receptors bind to both signaling proteins equally, and the importance of the phospholipid-binding domain in the signaling proteins remains unclear.</p><p>To shed light on the workings of these receptors, Lew et al. created mouse cells that each only express one out of the three TAM receptors. These cells were then exposed to intact Gas6 and Protein S, or shortened versions that lacked the phospholipid-binding domain. Lew et al. found that Gas6 could trigger a response through all three TAM receptors but that Protein S was specific for only two out of the three receptors. Signaling proteins with or without their phospholipid-binding domains bound equally well to the receptors, but the maximum level of response was only triggered when both signaling proteins were intact and the phospholipid molecule was present. This is important since the phospholipid can be thought of as an ‘eat-me’ signal by which the dead cells are recognized by the TAM receptor-expressing cells that will engulf them.</p><p>Using mice that only produce a TAM receptor called Mer, Lew et al. show that Protein S alone can trigger the process that engulfs and breaks down cells in a living organism. These data and previous work suggest that two TAM receptors—including Mer—are involved in the daily engulfment of dying cells, whereas the third mediates this process during infection and tissue damage.</p><p>Molecules that inhibit or activate the function of TAM receptors are currently being developed to treat cancer and other diseases. By revealing which receptors respond to which signaling molecules, the findings of Lew et al. will serve to guide these efforts.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.002">http://dx.doi.org/10.7554/eLife.03385.002</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author keywords</title><kwd>Gas6</kwd><kwd>Pros1</kwd><kwd>Axl</kwd><kwd>Mertk</kwd><kwd>Tyro3</kwd><kwd>receptor tyrosine kinase</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 AI077058, R01 AI101400, R01 NS085296, P30 CA014195</award-id><principal-award-recipient><name><surname>Lemke</surname><given-names>Greg</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100007028</institution-id><institution>Leona M. and Harry B. Helmsley Charitable Trust</institution></institution-wrap></funding-source><award-id>2012-PG-MED002</award-id><principal-award-recipient><name><surname>Lemke</surname><given-names>Greg</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100005189</institution-id><institution>Leukemia and Lymphoma Society</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lew</surname><given-names>Erin D</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution>Nomis Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lew</surname><given-names>Erin D</given-names></name><name><surname>Lemke</surname><given-names>Greg</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution>Fritz B. Burns Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lemke</surname><given-names>Greg</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>Haeyoung Kong Tang Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lemke</surname><given-names>Greg</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution>H.N and Frances C. Berger Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Lemke</surname><given-names>Greg</given-names></name></principal-award-recipient></award-group><award-group id="par-8"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000854</institution-id><institution>Human Frontier Science Program</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Zagórska</surname><given-names>Anna</given-names></name></principal-award-recipient></award-group><award-group id="par-9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000780</institution-id><institution>European Commission</institution></institution-wrap></funding-source><award-id>Marie Curie International Outgoing Fellowship Program</award-id><principal-award-recipient><name><surname>Través</surname><given-names>Paqui G</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Signaling by TAM receptor tyrosine kinases requires the coincident engagement of a TAM ligand with both its receptor and the phospholipid phosphatidylserine.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The three receptor tyrosine kinases of the TAM family–Tyro3, Axl, and Mer—are expressed in sentinel cells of the immune system, endothelial cells of the vasculature, neurons and glia of the nervous system, and professional phagocytes of the immune, nervous, and reproductive systems (<xref ref-type="bibr" rid="bib35">Lemke, 2013</xref>). In these settings, TAM signaling regulates multiple functions but two are especially prominent. The first is the ‘homeostatic’ or silent phagocytosis of the billions of apoptotic cells (ACs) that are generated on a daily basis throughout life (<xref ref-type="bibr" rid="bib68">Scott et al., 2001</xref>; <xref ref-type="bibr" rid="bib36">Lemke and Burstyn-Cohen, 2010</xref>). The second is the inhibition of the innate immune inflammatory response in dendritic cells (DCs), macrophages, and other sentinel cells of the immune system (<xref ref-type="bibr" rid="bib61">Rothlin et al., 2007</xref>; <xref ref-type="bibr" rid="bib38">Lemke and Rothlin, 2008</xref>). Deficiencies in TAM expression or activity lead to autoimmunity, blindness, and infertility (<xref ref-type="bibr" rid="bib42">Lu et al., 1999</xref>; <xref ref-type="bibr" rid="bib14">D'Cruz et al., 2000</xref>; <xref ref-type="bibr" rid="bib43">Lu and Lemke, 2001</xref>; <xref ref-type="bibr" rid="bib16">Duncan et al., 2003</xref>; <xref ref-type="bibr" rid="bib37">Lemke and Lu, 2003</xref>; <xref ref-type="bibr" rid="bib62">Rothlin and Lemke, 2010</xref>; <xref ref-type="bibr" rid="bib35">Lemke, 2013</xref>). Conversely, over-expression or aberrant activation of Tyro3, Axl, or Mer (gene name <italic>Mertk</italic>) is associated with the development, progression, and metastasis of cancers (<xref ref-type="bibr" rid="bib3">Avilla et al., 2011</xref>; <xref ref-type="bibr" rid="bib13">Cummings et al., 2013</xref>; <xref ref-type="bibr" rid="bib35">Lemke, 2013</xref>; <xref ref-type="bibr" rid="bib48">Meyer et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Paccez et al., 2014</xref>). Axl in particular has been shown to mediate the resistance of solid tumors and leukemias to epidermal growth factor receptor (EGFR)-directed chemotherapeutic agents (<xref ref-type="bibr" rid="bib25">Hong et al., 2008</xref>; <xref ref-type="bibr" rid="bib86">Zhang et al., 2012</xref>; <xref ref-type="bibr" rid="bib48">Meyer et al., 2013</xref>). Elevated TAM expression has also recently been implicated in increased susceptibility to infection by enveloped viruses (<xref ref-type="bibr" rid="bib71">Shimojima et al., 2006</xref>; <xref ref-type="bibr" rid="bib49">Morizono et al., 2011</xref>; <xref ref-type="bibr" rid="bib47">Meertens et al., 2012</xref>; <xref ref-type="bibr" rid="bib5">Bhattacharyya et al., 2013</xref>).</p><p>The importance of TAM activity notwithstanding, the differential signaling capacity of the two soluble ligands that activate TAM receptors—Gas6 and Protein S (gene and protein names Pros1) (<xref ref-type="bibr" rid="bib74">Stitt et al., 1995</xref>; <xref ref-type="bibr" rid="bib81">Varnum et al., 1995</xref>)—is incompletely understood. Gas6 is thought to function as a ligand for all three receptors (<xref ref-type="bibr" rid="bib74">Stitt et al., 1995</xref>; <xref ref-type="bibr" rid="bib50">Nagata et al., 1996</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 1997</xref>), but the role of Pros1 as a ligand for one or more TAM receptors has until recently been controversial (<xref ref-type="bibr" rid="bib22">Godowski et al., 1995</xref>; <xref ref-type="bibr" rid="bib1">Anderson et al., 2003</xref>; <xref ref-type="bibr" rid="bib23">Hafizi and Dahlback, 2006</xref>). At the same time, the unique structural features of Gas6 and Pros1—in which a C-terminal ‘SHBG domain’ binds to the Ig-like domains of TAM receptors while an N-terminal γ-carboxylated ‘Gla domain’ binds, in a Ca<sup>2+</sup>-dependent reaction, to the phospholipid phosphatidylserine (PtdSer) (<xref ref-type="bibr" rid="bib38">Lemke and Rothlin, 2008</xref>; <xref ref-type="bibr" rid="bib35">Lemke, 2013</xref>)—have led to conflicting conclusions as to the relative importance of these two domains in receptor binding vs activation (<xref ref-type="bibr" rid="bib45">Mark et al., 1996</xref>; <xref ref-type="bibr" rid="bib52">Nakano et al., 1997</xref>; <xref ref-type="bibr" rid="bib76">Tanabe et al., 1997</xref>). Although Gas6 and Pros1 binding to the PtdSer-containing membranes of enveloped viruses potentiates TAM activation (<xref ref-type="bibr" rid="bib47">Meertens et al., 2012</xref>; <xref ref-type="bibr" rid="bib5">Bhattacharyya et al., 2013</xref>), and the Gla domain is thought to be required to ‘bridge’ a TAM receptor expressed on the surface of a phagocyte to the PtdSer expressed on the surface of its AC target (<xref ref-type="bibr" rid="bib38">Lemke and Rothlin, 2008</xref>; <xref ref-type="bibr" rid="bib36">Lemke and Burstyn-Cohen, 2010</xref>; <xref ref-type="bibr" rid="bib51">Nagata et al., 2010</xref>), a preparation of recombinant mouse Gas6 that lacks the Gla domain entirely is sold commercially as a TAM activator.</p><p>Potentially distinct roles for Pros1 and Gas6 in vivo have only recently begun to be appreciated (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>; <xref ref-type="bibr" rid="bib9">Carrera Silva et al., 2013</xref>), and to date only a single genetic study of the importance of Gas6 vs Pros1 in a TAM-dependent process has been reported (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). This study addressed TAM signaling during the phagocytosis of photoreceptor (PR) outer segments by retinal pigment epithelial (RPE) cells (<xref ref-type="bibr" rid="bib75">Strauss, 2005</xref>), which express Mer and Tyro3 but no Axl (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>). RPE phagocytosis of the PtdSer-displaying tips of PR outer segments (<xref ref-type="bibr" rid="bib63">Ruggiero et al., 2012</xref>) requires Mer—mice, rats, and humans that carry loss-of-function mutations in the <italic>Mertk</italic> gene are blind, due to the cell-non-autonomous degeneration of nearly all PRs (<xref ref-type="bibr" rid="bib14">D'Cruz et al., 2000</xref>; <xref ref-type="bibr" rid="bib21">Gal et al., 2000</xref>; <xref ref-type="bibr" rid="bib16">Duncan et al., 2003</xref>; <xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib44">Mackay et al., 2010</xref>; <xref ref-type="bibr" rid="bib53">Nandrot and Dufour, 2010</xref>). This cell death results from the accumulation of toxic oxidated proteins that are generated during the course of phototransduction and are removed by phagocytosis. Retinal loss of either the mouse <italic>Gas6</italic> or <italic>Pros1</italic> gene alone yields a retina with a normal number of PRs, but the combined loss of <italic>Pros1</italic> and <italic>Gas6</italic> results in a PR degeneration phenotype that fully phenocopies the cell death seen in <italic>Mertk</italic><sup><italic>−/−</italic></sup> mice (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). While this analysis demonstrated that Pros1 is sufficient to drive Mer-dependent phagocytosis in RPE cells, the presence of Tyro3 in these cells raised the possibility that Pros1 activation of the Mer kinase might be dependent on Pros1 binding to Tyro3.</p><p>In the current study, we have used biochemistry, receptor activation profiling, and genetic analyses of single and compound mouse mutants to establish the basic rules for TAM ligand–receptor interaction, signaling, and function. We find that Gas6 activates all three TAM receptors, but is an especially potent ligand for Axl, with which it has a unique association. In contrast, Pros1 activates Tyro3 and Mer but is inactive as an Axl agonist. Notably, we find that the Gla domains of TAM ligands are dispensable for receptor binding but are critical for optimal receptor activation, and that for Gas6 activation of Axl, this requirement is absolute. We conclude that a complete TAM signaling module is composed of a receptor, a γ-carboxylated protein ligand, and the phospholipid PtdSer, a tripartite arrangement that is unique to the TAM family. Finally, we show that Mer is the functionally predominant TAM receptor in two different settings of ‘homeostatic’ PtdSer-dependent phagocytosis in vivo–in the retina and the testes–and that Pros1 binding to and activation of Mer alone is sufficient to ensure wild-type levels of phagocytosis in these settings.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Derivation of assay tools</title><p>We first generated highly pure preparations of recombinant mouse Gas6 and Pros1. We transfected pCEP4-based expression plasmids containing cDNAs for both full-length and Gla domain-deleted (‘Gla-less’) versions of these TAM ligands into HEK293 EBNA cells (<xref ref-type="bibr" rid="bib64">Sasaki et al., 2002</xref>) and selected stable transformants. Lines expressing the highest levels of each ligand were grown in serum-free production medium supplemented with vitamin K2, required for γ-carboxylation of Gla domain glutamic acid residues (<xref ref-type="bibr" rid="bib4">Bandyopadhyay, 2008</xref>). Ligands were purified to apparent homogeneity from conditioned medium, using affinity purification on a nickel-NTA resin followed by size exclusion and anion exchange chromatography (see ‘Materials and methods’).</p><p>All recombinant mouse ligands ran as single bands under reducing conditions on SDS polyacrylamide gels and eluted from an anion exchange column as a single peak suggesting that the ligands were pure (<xref ref-type="fig" rid="fig1">Figure 1A</xref> and data not shown). Commercially available Protein S purified from human plasma (hPros1) ran as a single predominant band under reducing conditions, together with a secondary band of lower molecular weight (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Size exclusion chromatography suggested that full-length Gas6 in solution is a mixture of monomers, dimers, and/or higher order multimers, whereas the Gla-less form appeared as a monomer (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). These elution profiles are consistent with earlier work on hPros1, indicating that it forms disulfide-linked multimers, and that multimerization is enhanced by apoptotic cells (<xref ref-type="bibr" rid="bib78">Uehara and Shacter, 2008</xref>).<fig-group><fig id="fig1" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.003</object-id><label>Figure 1.</label><caption><title>Recombinant TAM ligands and surface expression of TAM receptors.</title><p>(<bold>A</bold>) Purified recombinant full-length and Gla-less mouse Gas6 (rmGas6 and Gla-less rmGas6, respectively) and full-length and Gla-less Pros1 (rmPros1 and Gla-less rmPros1, respectively) were run under both reducing (r) and non-reducing (nr) conditions in SDS-PAGE. In parallel, purified human Pros1 (hPros1) was also run under reducing and non-reducing conditions. Gel was stained with Gel Code Blue (Pierce). (<bold>B</bold>) Live cell labeling of Tyro3 (top panels) and Axl (bottom panels) on the surface of clonal populations of TAM TKO MEF lines expressing HA-tagged recombinant mouse Tyro3 (left), recombinant mouse Axl (middle), or recombinant mouse Mer (right). Bar: 100 μm. (<bold>C</bold>) Induction of HA-tagged Mer expression in a Mer_TAM TKO MEF line in the presence of increasing concentrations of TetExpress transactivator protein (Clontech). In this and all the subsequent blots in which the HA tag was used for both immunoprecipitation (IP) and immunoblotting (IB), two different anti-HA antibodies were used: an anti-HA high affinity for IP and an anti-HA.11 for IB.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.003">http://dx.doi.org/10.7554/eLife.03385.003</ext-link></p></caption><graphic xlink:href="elife-03385-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03385.004</object-id><label>Figure 1—figure supplement 1.</label><caption><title>Size exclusion chromatography of full-length and Gla-less Gas6.</title><p>Purified full-length recombinant mouse Gas6 (rmGas6, black trace) and Gla-less rmGas6 (red trace) were loaded onto and eluted from a Superdex 200 HR 10/30 gel filtration column.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.004">http://dx.doi.org/10.7554/eLife.03385.004</ext-link></p></caption><graphic xlink:href="elife-03385-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03385.005</object-id><label>Figure 1—figure supplement 2.</label><caption><title>TAM receptor expression in immortalized cell lines.</title><p>Lysates from the indicated cell lines were subjected to SDS-PAGE and subsequent immunoblotting with antibodies against Tyro3 (top), Axl (middle), and Mer (bottom). Anti-Gapdh serves as a loading control. All established cell lines we have analyzed express at least one TAM receptor.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.005">http://dx.doi.org/10.7554/eLife.03385.005</ext-link></p></caption><graphic xlink:href="elife-03385-fig1-figsupp2-v2.tif"/></fig></fig-group></p><p>In order to have cellular assay targets in which individual TAM receptors could be expressed and their expression level normalized between cell lines, we first prepared immortalized mouse embryo fibroblast (MEF) lines from embryonic day (E)13.5 <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Axl</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> triple mutants (‘TAM TKO’) and all three possible double mutants (e.g., <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup>, or ‘TM DKO’) (<xref ref-type="bibr" rid="bib42">Lu et al., 1999</xref>; see ‘Materials and methods’). The TAM TKO MEF lines provide a baseline cell population that lacks expression of any TAM receptor and the double mutant lines isolate a single receptor. This was particularly important, since in surveys of established cell lines we were unable to identify any human, mouse, rat, hamster, or monkey immortalized line that did not express at least one endogenous TAM receptor. [Selected examples of TAM expression in cultured cells are shown in <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>] This suggests that all prior analyses of TAM receptor activation have been encumbered by the expression of endogenous Tyro3 and/or Axl and/or Mer.</p><p>We generated multiple clonal cell lines in the background of the TAM TKO MEFs that express HA-tagged versions of mouse Tyro3, Axl, and Mer, respectively. We then selected one clonal population from the Tyro3 and Axl sets that expressed equivalent levels of these receptors, based on detection of the HA tag (<xref ref-type="fig" rid="fig1 fig2">Figures 1B and 2D</xref>; see ‘Materials and methods’). Expression in these Tyro3- and Axl-expressing MEFs was not maximal among the clones we isolated but was physiological in that we did not observe receptor activation (autophosphorylation) in the absence of added ligand (<xref ref-type="fig" rid="fig2">Figure 2</xref>), a phenomenon frequently observed when RTKs are over-expressed. Although we were also able to isolate MEF lines expressing Mer, these lines always (for unknown reasons) expressed much lower levels of this receptor (<xref ref-type="fig" rid="fig1">Figure 1C</xref> and data not shown). For the Mer-expressing MEF line analyzed in this paper, we used a stable clonal line generated by expressing HA-tagged recombinant mouse Mer under the control of a TetExpress-inducible promoter (Clontech; <xref ref-type="fig" rid="fig1">Figure 1C</xref>). For the Tyro3- and Axl-expressing MEF lines, we used Tyro3 and Axl antibodies directed against the extracellular domains of the receptors to live label non-permeabilized cells in culture and demonstrate surface expression of the individual receptors (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). Mer expression in clonal, Tet-inducible Mer_TAM TKO MEF lines, while detectable by western blot (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), was too low to be detected by immunocytochemistry.<fig-group><fig id="fig2" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.006</object-id><label>Figure 2.</label><caption><title>Gas6 and Pros1 exhibit TAM receptor selectivity.</title><p>(<bold>A</bold>) Tyro3-expressing MEFs were stimulated with either human Pros1 (hPros1) or recombinant mouse Pros1 (rmPros1). (<bold>B</bold> and <bold>C</bold>) Tyro3-expressing MEFs were stimulated with increasing concentrations of full-length recombinant mouse Gas6 (rmGas6), recombinant mouse Pros1 (rmPros1, <bold>B</bold>), or purified human Pros1 (hPros1, <bold>C</bold>). (<bold>D</bold>) Tyro3- and Axl-expressing MEFs were stimulated with increasing concentrations of rmGas6. (<bold>E</bold>) Axl-expressing MEFs were stimulated with increasing concentrations of rmGas6 or rmPros1. (<bold>F</bold>) Tyro3- and Axl-expressing MEFs were stimulated with increasing concentrations of hPros1. (The lower molecular weight doublet in lanes 8–14 of the anti-pY blot of this panel, in lanes 1 and 8–11 of the anti-pY blot of panel <bold>E</bold>, and in lane 8 of the anti-pY blot of panel <bold>D</bold> is seen only in Axl-expressing MEFs in which Axl is not activated by exogenous ligand and its intensity does not increase with increasing concentration of hPros1 or rmPros1. It may represent basal Axl phosphorylation caused by low levels of MEF-produced (endogenous) Gas6. See also lanes 1 and 7–12 of the anti-pY blot of <xref ref-type="fig" rid="fig3">Figure 3B</xref>) (<bold>G</bold>) Mer-expressing MEFs were stimulated with increasing concentrations of rmGas6 or hPros1. (<bold>H</bold>) Dexamethasone-treated bone marrow-derived macrophages (Dex_Mϕ) were stimulated with increasing concentrations of rmGas6 or hPros1. Following stimulation with ligand for 10 min at 37°C, HA-tagged Tyro3 (<bold>A</bold>–<bold>D</bold> and <bold>F</bold>), Axl (<bold>D</bold>–<bold>F</bold>), Mer (<bold>G</bold>), or endogenous Mer (<bold>H</bold>, figure supplement 1) were immunoprecipitated from total cell lysates and subjected to SDS-PAGE and quantitative Licor western blotting (panels <bold>G</bold>, <bold>H</bold>, ECL western blotting system) with the indicated antibodies. In this and subsequent figures, receptor activation was assessed by blotting immunoprecipitates with an anti-phosphotyrosine antibody (pY).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.006">http://dx.doi.org/10.7554/eLife.03385.006</ext-link></p></caption><graphic xlink:href="elife-03385-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03385.007</object-id><label>Figure 2—figure supplement 1.</label><caption><title>Mer activation by rmGas6 and rmPros1.</title><p>Dex_Mφ were stimulated with increasing concentrations of rmGas6 or rmPros1.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.007">http://dx.doi.org/10.7554/eLife.03385.007</ext-link></p></caption><graphic xlink:href="elife-03385-fig2-figsupp1-v2.tif"/></fig></fig-group></p></sec><sec id="s2-2"><title>Distinct TAM receptor activation profiles for Gas6 and Pros1</title><p>We first assayed full-length recombinant mouse Gas6 and Pros1, together with purified human Pros1, for their ability to activate mouse Tyro3, Axl, and Mer. We measured activation of single receptors expressed in MEFs by monitoring their tyrosine phosphorylation 10 min after ligand addition to cells in serum-free medium, using immunoprecipitation with antibodies to the individual receptors (or their C-terminal HA tag) followed by immunoblotting with an anti-phosphotyrosine antibody (see ‘Materials and methods’). We found that both purified human and recombinant mouse Pros1 (hPros1 and rmPros1, respectively) were capable of rapidly activating Tyro3 autophosphorylation (<xref ref-type="fig" rid="fig2">Figure 2A–C</xref>). In our hands, purified hPros1 was more stable biochemically and often more potent than rmPros1 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>), and we therefore used the human protein for the majority of the Pros1 experiments described below. However, both the mouse and human ligands were active (<xref ref-type="fig" rid="fig2">Figure 2B,C</xref>). Consistent with these observations, both mouse and human Pros1 were also recently found to be active as ligands for a chimeric receptor comprised of the mouse Tyro3 ectodomain linked to the cytoplasmic domain of the R1 chain of the interferon (IFN)-gamma (γ) receptor (<xref ref-type="bibr" rid="bib77">Tsou et al., 2014</xref>). (Activation of this chimera, expressed in CHO cells, was monitored by tyrosine phosphorylation of STAT1.)</p><p>Mouse Tyro3 was also strongly activated by rmGas6 (<xref ref-type="fig" rid="fig2">Figure 2B–D</xref>). In contrast, we found that mouse Axl could only be activated by rmGas6 (<xref ref-type="fig" rid="fig2">Figure 2D–F</xref>). While we detected 10 min activation of Axl at rmGas6 concentrations as low as 1 nM (<xref ref-type="fig" rid="fig2">Figure 2D</xref>), we could not detect Axl activation by either mouse Pros1 (<xref ref-type="fig" rid="fig2">Figure 2E</xref>) or human Pros1 (<xref ref-type="fig" rid="fig2">Figure 2F</xref>) at any concentration tested. Correspondingly, hGas6 but not mPros1 has been found to induce STAT1 phosphorylation downstream of a chimeric mAxl/γR1 receptor expressed in CHO cells (<xref ref-type="bibr" rid="bib77">Tsou et al., 2014</xref>).</p><p>We used similar dose–response titrations to assess the ability of Gas6 and Pros1 to activate Mer. We found that both ligands were capable of activating this receptor in Mer-expressing MEFs, but that rmGas6 was more potent than hPros1 in this assay (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). Finally, as our Mer-expressing MEFs have much lower receptor levels than Tyro3 or Axl-expressing MEFs, we also performed the same analysis using dexamethasone-treated mouse bone marrow-derived macrophages (Dex_Mϕ). These cells have levels of Mer comparable to those of Tyro3 or Axl in the MEF cell lines and do not express any other TAM receptor (<xref ref-type="bibr" rid="bib46">McColl et al., 2009</xref>; <xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>; and data not shown). We found that both rmGas6 and hPros1/rmPros1 also function as a ligand for Mer in these cells (<xref ref-type="fig" rid="fig2">Figure 2H</xref> and <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>).</p></sec><sec id="s2-3"><title>The Gas6 Gla domain is essential for optimal TAM receptor activation</title><p>Together with several components of the blood coagulation cascade, including prothrombin, Protein C, and factors VII, IX, and X, both Gas6 and Pros1 carry ‘Gla domains’—polypeptide segments of ∼45 amino acids that contain clusters of 10–12 glutamic acid residues whose gamma carbons are post-translationally carboxylated in a vitamin K-dependent reaction (<xref ref-type="bibr" rid="bib74">Stitt et al., 1995</xref>; <xref ref-type="bibr" rid="bib54">Nelsestuen et al., 2000</xref>; <xref ref-type="bibr" rid="bib27">Huang et al., 2003</xref>; <xref ref-type="bibr" rid="bib4">Bandyopadhyay, 2008</xref>). This γ-carboxylation of glutamic acid is required for the Ca<sup>2+</sup>-dependent binding of Gla domains to PtdSer, which is displayed on the surface of apoptotic cells (ACs) and enveloped viruses (<xref ref-type="bibr" rid="bib5">Bhattacharyya et al., 2013</xref>). It is indispensible for the bioactivity of the Gla domain-containing proteins of the coagulation cascade and is a principal reason that vitamin K is an essential vitamin (<xref ref-type="bibr" rid="bib20">Freedman et al., 1995</xref>; <xref ref-type="bibr" rid="bib29">Ishimoto et al., 2000</xref>; <xref ref-type="bibr" rid="bib4">Bandyopadhyay, 2008</xref>; <xref ref-type="bibr" rid="bib60">Rajotte et al., 2008</xref>; <xref ref-type="bibr" rid="bib35">Lemke, 2013</xref>). The anticoagulant warfarin and related blood thinners antagonize vitamin K-dependent γ-carboxylation of Gla domains (<xref ref-type="bibr" rid="bib73">Stafford, 2005</xref>).</p><p>We first compared the ability of full-length vs Gla-less mouse Gas6 to activate Tyro3. Gla-less Gas6 is deleted for the first 115 residues of the protein, including the Gla domain, but retains all four EGF-like domains and the SHBG-like domain. We found that although both full-length and Gla-less rmGas6 were capable of activating Tyro3, the full-length protein was markedly (∼20-fold) more potent (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). When we performed this same comparison for Axl-expressing MEFs, we observed an even stronger dependence. Full-length Gas6 was a very potent Axl ligand (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, left 6 lanes), but the Gla-less version was incapable of activating Axl at any concentration tested (up to 750 nM; <xref ref-type="fig" rid="fig3">Figure 3B</xref>, right 6 lanes). We found that this stark disparity was unique to Axl. When we compared the ability of full-length and Gla-less rmGas6 to activate Mer in Mer-expressing Dex-Mϕ, we observed a pattern similar to that seen for Tyro3. Although both forms of the ligand were capable of activating Mer, full-length Gas6 was ∼20-fold more potent than its Gla-less counterpart (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Thus, the TAM receptors fall into two groups based on features of their ligand and PtdSer activation profiles: Tyro3 and Mer are activated by both Gas6 and Pros1, whereas Axl is activated only by Gas6; and while Gla-less Gas6 is a substantially weaker ligand for Tyro3 and Mer, it is effectively dead as a ligand for Axl.<fig id="fig3" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.008</object-id><label>Figure 3.</label><caption><title>The role of the Gla domain in TAM receptor activation.</title><p>(<bold>A</bold>, <bold>B</bold>, <bold>C</bold>) Tyro3-expressing MEFs, Axl-expressing MEFs, or dexamethasone-treated BM-derived macrophages expressing Mer, respectively, were stimulated with the indicated increasing concentrations of full-length rmGas6 or Gla-less rmGas6, respectively. Total cell lysates were immunoprecipitated with either HA antibodies (<bold>A</bold> and <bold>B</bold>) or Mer-specific antibodies (<bold>C</bold>) and subsequently subjected to SDS-PAGE and quantitative Licor western blotting (panel <bold>C</bold>, ECL western blotting) with the indicated antibodies. (<bold>D</bold>) MEFs expressing Axl or a chimeric receptor composed of the Tyro3 extracellular domain linked to the Axl tyrosine kinase domain (ECD<sub>T</sub>TK<sub>A</sub>) were stimulated with either full-length rmGas6 or Gla-less Gas6. Receptors were immunoprecipitated from cell lysates using an HA antibody, and immunoprecipitates were subjected to SDS-PAGE and Licor western blotting with anti-phosphotyrosine and HA antibodies. The higher basal activation of the ECD<sub>T</sub>TK<sub>A</sub> construct may reflect its higher level of expression. (<bold>E</bold>) Binding assays were performed on Axl-expressing MEFs using a single concentration of <sup>125</sup>I-labeled full-length rmGas6 in the presence of increasing concentrations of either unlabeled full-length rmGas6 (black) or Gla-less rmGas6 (red). Measured concentrations of unlabeled ligand required for 50% inhibition of displaceable binding (IC<sub>50</sub>) are indicated.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.008">http://dx.doi.org/10.7554/eLife.03385.008</ext-link></p></caption><graphic xlink:href="elife-03385-fig3-v2.tif"/></fig></p><p>The difference in the ability of Gla-less Gas6 to activate Axl vs Tyro3/Mer is unrelated to any difference in the intrinsic tyrosine kinase activity of the three receptors. We found that a Tyro3–Axl chimeric receptor composed of the Tyro3 extracellular domain linked to the Axl tyrosine kinase, when expressed in TAM TKO MEFs, displayed diminished activation by Gla-less Gas6 similar to that seen with Tyro3 (<xref ref-type="fig" rid="fig3">Figure 3A,D</xref>). This suggests that the interaction of Gla-less Gas6 to Tyro3 and Mer is distinct structurally from its interaction with Axl. Together, these results indicate that the Gas6 Gla domain is required for optimal activation of Tyro3 and Mer, and that this requirement is absolute for Axl.</p></sec><sec id="s2-4"><title>The Gas6 Gla domain is dispensable for Axl binding</title><p>We asked whether the marked difference in Axl activation displayed by full-length vs Gla-less rmGas6 was reflected in a difference in Axl binding. Since there have been conflicting reports as to the relative binding affinity of full-length vs Gla-less Gas6 to Axl-Fc fusion proteins, as measured by using BIAcore sensor chips (<xref ref-type="bibr" rid="bib52">Nakano et al., 1997</xref>; <xref ref-type="bibr" rid="bib76">Tanabe et al., 1997</xref>; <xref ref-type="bibr" rid="bib15">Demarest et al., 2013</xref>), we measured their Axl binding affinities in a more biologically relevant context; that is, to intact Axl receptor expressed on the surface of TM DKO MEFs (prepared from <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> embryos) in culture. We radio-iodinated full-length rmGas6 and then performed conventional competitive binding assays using displacement with increasing concentrations of either unlabeled full-length Gas6 or unlabeled Gla-less Gas6 (see ‘Materials and methods’).</p><p>We found that full-length and Gla-less Gas6 displayed essentially the same IC<sub>50</sub> for Axl binding—approximately 0.7 nM in this assay (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Thus, the inability of Gla-less Gas6 to activate Axl is unrelated to its ability to bind the receptor; and conversely, the ability of a Gas6 variant to bind Axl is unrelated to its ability to activate the receptor. These properties suggest that a crystal structure of the Axl ectodomain bound to Gla-less Gas6 (<xref ref-type="bibr" rid="bib65">Sasaki et al., 2006</xref>) represents a ligand-occupied but inactive Axl configuration. In related work, we have found that these properties are also exceptionally important to Gas6–Axl binding and signaling in tissues in vivo, where Gas6 appears to be specifically and constitutively bound to Axl without significant activation of the receptor (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>). Consistent with the failure of Pros1 to activate Axl in culture (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref>), we detected no binding of Pros1 to Axl-expressing MEFs (data not shown).</p></sec><sec id="s2-5"><title>Phosphatidylserine is present in MEF cultures</title><p>The importance of PtdSer for TAM ligand activity suggests that this phospholipid must be available to the purified TAM ligands that are added to MEF cultures (as in <xref ref-type="fig" rid="fig2 fig3">Figures 2 and 3</xref>). This is in spite of the fact that PtdSer is largely confined to the inner leaflet of the plasma membrane bilayer of non-apoptotic cells through the action of a set of P<sub>4</sub>-ATPases—so-called flippases (<xref ref-type="bibr" rid="bib80">van Meer et al., 2008</xref>). Consistent with this hypothesis, we found that the PtdSer-binding protein Annexin A5 antagonized Gas6 activation of Tyro3 in Tyro3_TAM TKO MEFs (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). We therefore probed for the presence of PtdSer in MEF cultures directly. We co-incubated MEFs (grown under the same conditions we used for activation studies) with propidium iodide (PI) and the fluorescent Annexin B12 derivative pSIVA, a polarity-sensitive biosensor that fluoresces only when bound to PtdSer (<xref ref-type="bibr" rid="bib30">Kim et al., 2010</xref>; <xref ref-type="bibr" rid="bib63">Ruggiero et al., 2012</xref>), and then analyzed the cells by flow cytometry. We detected significant number of pSIVA<sup>+</sup>PI<sup>−</sup> apoptotic cells and pSIVA<sup>+</sup>PI<sup>+</sup> late apoptotic/necrotic cells in the culture medium and even a measurable number of pSIVA<sup>+</sup>PI<sup>−</sup> and pSIVA<sup>+</sup>PI<sup>+</sup> cells in the adherent MEFs on the plate (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Together, these results demonstrate that there are PtdSer-displaying membranes present in the MEF cultures. It is important to note that the molecular weight of PtdSer is ∼385 g/mol, while Gas6 and Pros1 have molecular weights of ∼80,000 g/mol, and that the crystal structure of the prothrombin Gla domain bound to lyso-PtdSer contains only a single molecule of this phospholipid (<xref ref-type="bibr" rid="bib27">Huang et al., 2003</xref>). Thus, a relatively low level of PtdSer can easily be in molar excess over the Gla domain-containing proteins with which it interacts. In this regard, the addition of either PtdSer-displaying enveloped viruses (<xref ref-type="bibr" rid="bib5">Bhattacharyya et al., 2013</xref>) or PtdSer-displaying apoptotic cells (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>) has been found to markedly shift the dose–response curves for Pros1 activation of Mer and Gas6 activation of Axl/Mer to lower ligand concentrations.<fig id="fig4" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.009</object-id><label>Figure 4.</label><caption><title>Phosphatidylserine and TAM activation.</title><p>(<bold>A</bold>) Tyro3-expressing MEFs were treated with the indicated concentrations of Annexin A5 for 10 min and then stimulated with 5 nM full-length rmGas6 for 10 min. Total cell lysates were immunoprecipitated with HA antibodies and subsequently subjected to SDS-PAGE and western blotting with the indicated antibodies. (<bold>B</bold>) FACS analysis. Adherent cells (left) and cells from culture medium (‘supernatant’, right) from Axl_TAM TKO MEF cultures were analyzed by staining with propidium iodide, which is only taken up by dead cells, and pSIVA, which only fluoresces when bound to PtdSer (right panels). Numbers in the four quadrants of the panels indicate percent of signal in that quadrant. 21.2% of the gated material in the MEF culture supernatant (upper right quadrant in the right panel) represents PtdSer-expressing apoptotic cells. (<bold>C</bold> and <bold>D</bold>) Axl_TAM TKO MEFs (<bold>C</bold>) and control TAM TKO MEFs (<bold>D</bold>) were incubated +/− rmGas6 or Gla-less rmGas6 (as indicated) and +/− 10 mM EDTA for 90 min at 4°C and then live-stained with an anti-Gas6 antibody (green) and Hoechst to visualize nuclei. (<bold>E</bold>) Axl-expressing Axl_TAM TKO MEFs were stimulated +/− 10 nM rmGas6 in the presence of the indicated concentrations of EDTA for 10 min. Total cell lysates were either: (top two blots) immunoprecipitated with HA antibodies and subsequently subjected to SDS-PAGE and western blotting with the indicated antibodies; or (bottom three loading control blots) western blotted with the indicated antibodies. Scale bar (for <bold>C</bold> and <bold>D</bold>) 50 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.009">http://dx.doi.org/10.7554/eLife.03385.009</ext-link></p></caption><graphic xlink:href="elife-03385-fig4-v2.tif"/></fig></p></sec><sec id="s2-6"><title>Gas6 binding to Axl is calcium independent but Gas6 activation of Axl is calcium dependent</title><p>The binding of Gla domains to PtdSer is also Ca<sup>2+</sup>-dependent (<xref ref-type="bibr" rid="bib27">Huang et al., 2003</xref>) and can be rapidly disrupted by Ca<sup>2+</sup>-chelating agents such as EDTA. We therefore used immunocytochemistry to ask if rmGas6 binding to Axl in Axl-expressing MEFs is Ca<sup>2+</sup>-dependent. We found that it is not: binding of rmGas6 (at 25 nM) to the surface of Axl-expressing MEFs was readily observed with an anti-Gas6 antibody at 90 min after application (at 4°C), and this binding was unaffected by the inclusion of 10 mM EDTA (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). We also detected equivalent binding of Gla-less Gas6 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In control experiments, no Gas6 binding was detected in TAM TKO MEFs (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). These results argue that the observed Gas6 binding is via SHBG domain binding to Axl and not via Gla domain binding to any PtdSer expressed by the MEFs. We then asked whether Gas6 bound to Axl in the presence of EDTA (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, third panel) is capable of activating Axl. We found that it is not: although 10 nM rmGas6 resulted in strong Axl activation in the absence of EDTA, the inclusion of 2, 10, or 50 mM EDTA all blocked this activation (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). These results indicate that the binding of full-length Gas6 alone, in the absence of simultaneous Ca<sup>2+</sup>-dependent binding of its Gla domain to PtdSer, is insufficient to trigger Axl activation.</p></sec><sec id="s2-7"><title>Gas6 activation of Axl in vivo</title><p>We next extended these cell culture observations to an in vivo setting. We injected either full-length or Gla-less rmGas6 intravenously (IV) into <italic>Gas6</italic><sup><italic>−/−</italic></sup> mice and then used immunohistochemistry to monitor the binding of these injected proteins to splenic red pulp macrophages. F4/80<sup>+</sup> red pulp macrophages express both Axl and Mer and are normally also Gas6<sup>+</sup> (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>). By 30 min after IV injection, we observed equally strong binding of both full-length and Gla-less rmGas6 to these cells (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). However, this equivalent in vivo binding was not reflected in equivalent Axl activation. When we immunoprecipitated Axl from the spleen 30 min after IV injection of full-length Gas6, we observed that Axl was strongly activated (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). In marked contrast, Axl immunoprecipitated after injection of Gla-less rmGas6 showed zero activation (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). This was in spite of the fact that equivalent amounts of full-length and Gla-less Gas6 could be recovered from the spleen (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). The PtdSer required for activation of Axl by full-length rmGas6 injected IV is presumably provided by both apoptotic cells and circulating PtdSer-exposing microparticles, derived from platelets, erythrocytes, leukocytes, and endothelial cells, which are abundant in the blood (<xref ref-type="bibr" rid="bib32">Lacroix and Dignat-George, 2012</xref>).<fig id="fig5" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.010</object-id><label>Figure 5.</label><caption><title>Gla-less Gas6 binds but does not activate Axl in vivo.</title><p>(<bold>A</bold>) Sections of spleens from <italic>Gas6</italic><sup><italic>−/−</italic></sup> mice 30 min after IV injection of saline (top row), 30 μg full-length rmGas6 (middle row), or 30 μg Gla-less rmGas6 (bottom row), and stained with an anti-Gas6 antibody (first column, green) and an anti-F4/80 antibody to identify splenic red pulp macrophages (second column, red). Merged images from the first and second columns are displayed in the third column. (<bold>B</bold>) Splenic lysates from <italic>Gas6</italic><sup><italic>−/−</italic></sup> mice injected IV as in (<bold>A</bold>) were immunoprecipitated with the indicated antibodies 30 min after injection, and the immunoprecipitates then immunoblotted for pY and Axl (top two panels), pY and Tyro3 (middle two panels), or Gas6 (bottom panel).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.010">http://dx.doi.org/10.7554/eLife.03385.010</ext-link></p></caption><graphic xlink:href="elife-03385-fig5-v2.tif"/></fig></p></sec><sec id="s2-8"><title>TAM signaling differences reside in the Ig-like domains of the receptors</title><p>We found that the distinct receptor–ligand activation profiles described above reflect differences that are intrinsic to the Ig-like domains of the TAM ectodomains. We compared the ability of rmGas6 and hPros1 to activate TAM receptor autophosphorylation in MEF lines expressing either full-length Tyro3 or a chimeric receptor composed of the Tyro3 extracellular domain linked to the tyrosine kinase domain of Axl (<xref ref-type="fig" rid="fig6">Figure 6A</xref>). This chimeric receptor was also expressed well in clonal TAM TKO MEF lines (<xref ref-type="fig" rid="fig6">Figure 6B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). The activation profiles of both rmGas6 (<xref ref-type="fig" rid="fig6">Figure 6C</xref>) and hPros1 (<xref ref-type="fig" rid="fig6">Figure 6D</xref>) were similar for MEF lines expressing equivalent levels of wild-type Tyro3 or the chimeric Tyro3–Axl hybrid. We found that specificity resides within the two N-terminal Ig-like domains of the receptors, and that both of these domains are required: a hybrid receptor composed of the two Ig-like domains of Tyro3 linked to the remaining domains of Axl (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) was, like Tyro3, potently activated by Pros1 (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, lanes 5–8), whereas a chimera that contained only the first Ig-like domain of Tyro3 (<xref ref-type="fig" rid="fig6">Figure 6A</xref>) was refractory to activation by Pros1 (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, lanes 1–4). These results indicate that the intrinsic catalytic activity of Axl and Tyro3 are stimulated to comparable levels by ligand binding—of either Gas6 or Pros1–to the Tyro3 extracellular domain.<fig-group><fig id="fig6" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.011</object-id><label>Figure 6.</label><caption><title>Differences in TAM receptor activation are not due to differences in TAM kinase activity.</title><p>(<bold>A</bold>) Schematic of wild-type Tyro3 and Axl, a Tyro3/Axl chimeric receptor carrying the complete Tyro3 ectodomain linked to the Axl transmembrane (TM) and tyrosine kinase (TK) domains (ECD<sub>T</sub>TK<sub>A</sub>), and chimeric receptors carrying both Tyro3 Ig domains (ECD<sub>TIgI/II</sub>TK<sub>A</sub>) or only the first Tyro3 Ig domain (ECD<sub>TIgI</sub>TK<sub>A</sub>). FnIII: fibronectin type III repeat. (<bold>B</bold>) Immunostaining of Tyro3-, Axl-, and Tyro3/Axl chimera expressing TAM TKO MEFs, using an anti-HA antibody (green). Bar: 50 μm. (<bold>C</bold> and <bold>D</bold>) MEFs expressing Tyro3 or the indicated Tyro3/Axl chimeric receptors were stimulated with increasing concentrations of either rmGas6 or hPros1, respectively. Cell lysates were immunoprecipitated with anti-HA antibodies and subjected to SDS-PAGE electrophoresis followed by quantitative Licor western blotting with the indicated antibodies.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.011">http://dx.doi.org/10.7554/eLife.03385.011</ext-link></p></caption><graphic xlink:href="elife-03385-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03385.012</object-id><label>Figure 6—figure supplement 1.</label><caption><title>Surface expression of Tyro3/Axl chimeric receptors.</title><p>Live cell labeling of surface expression of Tyro3 or Tyro3/Axl chimeric receptors, respectively. Cells were incubated with Tyro3 and Axl antibodies in combination on ice for 1.5 hr. Scale bar: 50 µm.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.012">http://dx.doi.org/10.7554/eLife.03385.012</ext-link></p></caption><graphic xlink:href="elife-03385-fig6-figsupp1-v2.tif"/></fig></fig-group></p></sec><sec id="s2-9"><title>Genetic delineation of TAM receptor–ligand interactions in the retina</title><p>We extended our in vitro observations of differential TAM interactions to two in vivo settings in which genetic analyses have shown that TAM signaling plays an essential role. The first of these is the phagocytosis of the distal tips of photoreceptor's (PR) outer segments by the retinal pigment epithelial (RPE) cells of the eye (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). As noted above, Mer is absolutely required for this phagocytosis (<xref ref-type="bibr" rid="bib14">D'Cruz et al., 2000</xref>; <xref ref-type="bibr" rid="bib16">Duncan et al., 2003</xref>; <xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib53">Nandrot and Dufour, 2010</xref>; <xref ref-type="bibr" rid="bib57">Ostergaard et al., 2011</xref>). In <italic>Mertk</italic><sup><italic>−/−</italic></sup> mice, a phagocytic deficiency results in the nearly complete death of PRs by 12 weeks of age (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). We have previously shown that <italic>Tyro3</italic> mouse mutants, <italic>Gas6</italic> mouse mutants, and retina-specific <italic>Pros1</italic> mouse mutants all have a normal number of PRs at this time (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>); but that <italic>Gas6/Pros1</italic> double mutants display PR death and retinal degeneration that fully phenocopies the degeneration of the <italic>Mertk</italic> mutants (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>).</p><p>These analyses demonstrate that Pros1 acts as an effective Mer activator during RPE cell phagocytosis but not that this occurs through direct binding of Pros1 to Mer. To address this question, we generated <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Gas6</italic><sup><italic>−/−</italic></sup> double mutants. In these mice, the only TAM ligand remaining is Pros1, and the only TAM receptor through which it can bind and signal in RPE cells is Mer. As noted above, RPE cells do not express Axl (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>), which, in addition, is only activated by Gas6 (<xref ref-type="fig" rid="fig2">Figure 2E,F</xref>). As described previously, PR death can be assessed quantitatively in retinal sections by measuring the radial thickness of the outer nuclear layer (ONL), which is composed exclusively of PR nuclei (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). In 10–12-week old wild-type (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, first panel), <italic>Gas6</italic><sup><italic>−/−</italic></sup> (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, third panel), and <italic>Tyro3</italic><sup><italic>−/−</italic></sup> retinae (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, fourth panel), the ONL has a normal radial thickness of ∼50 μm and consists of 12–15 compact PR nuclei (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). In marked contrast, the <italic>Mertk</italic><sup><italic>−/−</italic></sup> ONL is reduced to a thickness of only 1–4 PR nuclei (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, second panel) (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). (The <xref ref-type="fig" rid="fig7">Figure 7A</xref> panel illustrates a region of severe PR degeneration in which the ONL is only one nucleus thick.) We found that the <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Gas6</italic><sup><italic>−/−</italic></sup> ONL is also of wild-type thickness (<xref ref-type="fig" rid="fig7">Figure 7A</xref>, fifth panel). Thus, Pros1–Mer signaling alone is sufficient to mediate apparently normal phagocytosis in the retina.<fig id="fig7" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.013</object-id><label>Figure 7.</label><caption><title>The Pros1–Mer signaling axis is sufficient for RPE phagocytosis in the retina.</title><p>(<bold>A</bold>) Dorsal–ventral H&amp;E stained sections from 12–14 week mouse retinae. The outer nuclear layer (ONL), composed exclusively of PR nuclei, is delimited by the vertical white line. The ONL in the <italic>Mertk</italic><sup><italic>−/−</italic></sup> mutant (second panel) is reduced to a thickness of a single nucleus (arrow) and the outer segment (OS) layer above is absent. In contrast, the ONL in the <italic>Gas6</italic><sup><italic>−/−</italic></sup>, <italic>Tyro3</italic><sup><italic>−/−</italic></sup>, and the <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Gas6</italic><sup><italic>−/−</italic></sup> retinae is of a thickness that is indistinguishable from wild-type control. Bar: 50 μm. (<bold>B</bold>) Pros1-mediated activation of Mer in the RPE cell layer is independent of Tyro3 expression. Eye cups were acutely isolated from wild-type and <italic>Tyro3</italic><sup><italic>−/−</italic></sup> mice. Cornea, iris, and lens were removed, leaving the RPE cell layer exposed. The eyecup was cultured under starvation conditions for 3 hr, and subsequently stimulated with increasing concentrations of hPros1. Cell lysates were immunoprecipitated with anti-Tyro3 or anti-Mer antibodies and receptor activation monitored by immunoblotting with anti-phosphotyrosine antibody (pY).</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.013">http://dx.doi.org/10.7554/eLife.03385.013</ext-link></p></caption><graphic xlink:href="elife-03385-fig7-v2.tif"/></fig></p><p>We also assessed the ability of hPros1 to activate Mer in a dissected RPE layer preparation in vitro (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). As before (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>), we isolated the eyecup from either wild-type or <italic>Tyro3</italic><sup><italic>−/−</italic></sup> adult mice and removed the cornea, lens, and retina to leave the apical surface of the RPE cell layer exposed. We then treated this surface, where Mer and Tyro3 are localized (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>), with hPros1. We have shown previously that purified Pros1 can enhance Mer autophosphorylation in this preparation (<xref ref-type="bibr" rid="bib59">Prasad et al., 2006</xref>; <xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). As shown in <xref ref-type="fig" rid="fig7">Figure 7B</xref> (upper two panels), we demonstrate that purified Pros1 can also activate Tyro3 in this preparation and can activate Mer in both wild-type and <italic>Tyro3</italic><sup><italic>−/−</italic></sup> RPE cells (<xref ref-type="fig" rid="fig7">Figure 7B</xref>, lower two panels). Thus, Pros1 induces Mer autophosphorylation in the RPE directly, in the absence of any other TAM receptor, and this Pros1-to-Mer activation alone is sufficient to maintain a normal number of PRs in the retina in vivo.</p></sec><sec id="s2-10"><title>Genetic delineation of TAM receptor–ligand interactions in the testes</title><p>A second setting in which PtdSer-dependent TAM signaling plays an essential role is the homeostatic phagocytosis of apoptotic cells in the seminiferous tubules of the testes (<xref ref-type="bibr" rid="bib42">Lu et al., 1999</xref>). This setting is distinct from retina, where RPE cells phagocytize only a portion of a living cell. In the testes, Sertoli cells must engulf and clear millions of apoptotic germ cells that are generated normally during every cycle of mammalian spermatogenesis (&gt;10<sup>8</sup>/day in a human male). Sertoli cells express all three TAM receptors and both ligands (<xref ref-type="bibr" rid="bib42">Lu et al., 1999</xref>; <xref ref-type="bibr" rid="bib11">Chen et al., 2009</xref>), and <italic>Tyro3/Axl/Mer</italic> triple mouse mutants are infertile due to the toxic accumulation of ACs (<xref ref-type="bibr" rid="bib42">Lu et al., 1999</xref>). We used immunostaining with antibodies to activated (cleaved) caspase 3 (cCasp3; see ‘Materials and methods’) to quantify the number of ACs present in the 10–12-week seminiferous tubules across an informative set of TAM receptor and ligand mutants. We counted all activated cCasp3<sup>+</sup> cells throughout an entire testis section and then normalized these counts to the number of tubule cross-sections present per testis section, which averaged 262.1 ± 20.6 (1 S.D.) and did not vary significantly for any of the genotypes we analyzed (data not shown).</p><p>We found that the major receptor required for Sertoli cell phagocytosis of apoptotic germ cells in the mouse testis is Mer (<xref ref-type="fig" rid="fig8">Figure 8A,B</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). While <italic>Tyro3</italic><sup><italic>−/−</italic></sup>, <italic>Axl</italic><sup><italic>−/−</italic></sup>, and <italic>Gas6</italic><sup><italic>−/−</italic></sup> single mutant mice all displayed wild-type number of cCasp3<sup>+</sup> ACs—∼0.02 cells per tubule cross-section (<xref ref-type="fig" rid="fig8">Figure 8A</xref>, and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>)–<italic>Mertk</italic><sup><italic>−/−</italic></sup> mice displayed nearly 20 times more (<xref ref-type="fig" rid="fig8">Figure 8B</xref>). In contrast to other tissues we have analyzed (e.g., the spleen), the number of ACs was not increased in <italic>Mertk</italic><sup><italic>−/−</italic></sup><italic>Axl</italic><sup><italic>−/−</italic></sup> double knock-outs compared to <italic>Mertk</italic><sup><italic>−/−</italic></sup> single knock-outs (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A,C</xref>). More tellingly, <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Axl</italic><sup><italic>−/−</italic></sup> double knock-outs displayed wild-type number of ACs in the testes (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A,C</xref>), and this was also the case for <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Gas6</italic><sup><italic>−/−</italic></sup> double knock-outs, in which the only possible TAM signaling axis is Pros1 to Mer (<xref ref-type="fig" rid="fig8">Figure 8A,B</xref>).<fig-group><fig id="fig8" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.014</object-id><label>Figure 8.</label><caption><title>Pros1–Mer signaling is sufficient for TAM-dependent homeostatic clearance of apoptotic cells in the testis.</title><p>(<bold>A</bold>) Representative H&amp;E images (top row) or immunostaining for cleaved caspase 3 (cCasp3) (bottom row) in testis sections from 12–14 week old wild-type and TAM ligand and/or TAM receptor mutants. For the <italic>Mertk</italic><sup><italic>−/−</italic></sup> sections (second column), apoptotic cells are highlighted with white asterisks in the H&amp;E-stained section, and cCasp3+ cells are highlighted with black asterisks. Bar: 100 μm. (<bold>B</bold>) Quantitative analysis of the number of apoptotic cells in wild-type and various TAM receptor/ligand mutants. Cleaved caspase 3+ cells and tubule cross-sections were counted in four testis cross-sections per mouse. Data are expressed as average number of ACs per number of total tubule cross-sections in each testis section. Error bars represent standard error of the mean for three independent animals. (<bold>C</bold>) TAM receptor expression in TAM receptor and TAM ligand mouse mutants. Testes were collected from 12- to 14-week old mice of the indicated genotypes and lysed. Lysates were subjected to SDS-PAGE and immunoblotting with anti-Tyro3, Axl, and Mer antibodies, with anti-Akt serving as a loading control. (<bold>D</bold>) Comparative analysis of TAM expression in the testis. Lysates from either wild-type testis or TAM TKO MEFs expressing HA-tagged Tyro3, Axl, or Mer were subjected to SDS-PAGE and subsequent quantitative Licor immunoblotting with the indicated antibodies. (<bold>E</bold>) Band intensity of the HA-tagged TAM receptors relative to each other and to wild-type testis was calculated using Licor Odyssey software and utilized to calculate the TAM protein expression relative to Tyro3 in the wild-type testis.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.014">http://dx.doi.org/10.7554/eLife.03385.014</ext-link></p></caption><graphic xlink:href="elife-03385-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><object-id pub-id-type="doi">10.7554/eLife.03385.015</object-id><label>Figure 8—figure supplement 1.</label><caption><title>Tyro3 and Mer are key regulators of homeostatic apoptotic cell clearance in the testis.</title><p>(<bold>A</bold>) Representative H&amp;E images (top rows) and immunostaining for cCasp3 (bottom rows) in 10- to 12-week old wild-type and TAM-deficient animals of the indicated genotypes. All mice except for TAM TKOs were on a pure C57Bl/6 background. Bar is 100 μm. (<bold>B</bold>) Comparison of the number of apoptotic cells identified by cCasp3 immunostaining in wild-type (WT) and <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Mer</italic><sup><italic>−/−</italic></sup> double mutant testis at 10–12 weeks (young) vs the same genotypes at 9–12 months (old). Bar is 100 μm. (<bold>C</bold>) Quantitative analysis of apoptotic (cleaved Casp3<sup>+</sup>) cells in wild-type and various TAM ligand and/or TAM receptor mutants. Apoptotic cells as determined by cCasp3 staining and tubule cross-sections were counted in four testis sections per animal and averaged per number of total tubule cross-sections. All mice except for TAM TKOs were on a pure C57Bl/6 background. Error bars represent standard error of the mean for three independent animals (<italic>Pros1</italic><sup><italic>f/−</italic></sup><italic>Gas6</italic><sup><italic>−/−</italic></sup>, n = 2). (<bold>D</bold>) Quantitative analysis as in (<bold>C</bold>) for the young/old testis comparison illustrated in (<bold>B</bold>). These mice were on a hybrid C57Bl/6 × 129sv background.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.015">http://dx.doi.org/10.7554/eLife.03385.015</ext-link></p></caption><graphic xlink:href="elife-03385-fig8-figsupp1-v2.tif"/></fig></fig-group></p><p>In contrast to the retina, we observed a significant effect of <italic>Tyro3</italic> mutation in the presence of an existing <italic>Mertk</italic> mutation: <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> double mutants displayed substantially more ACs in the testis (∼2 cCasp3<sup>+</sup> cells per each tubule cross-section) than did <italic>Mertk</italic><sup><italic>−/−</italic></sup> single mutants (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A,C</xref>). Combining all three receptor knock-outs in <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Axl</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> triple mutants led to a massive accumulation of ACs and cCasp3<sup>+</sup> material that made accurate counting of ACs impossible (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref>). This suggests that in the absence of Mer and Tyro3, Axl can also mediate AC phagocytosis. Finally, we examined the effect of removing all Gas6 and half the normal Pros1 throughout the mouse and found that the <italic>Pros</italic><sup><italic>fl/−</italic></sup><italic>Gas6</italic><sup><italic>−/−</italic></sup> testes also contained a wild-type number of ACs (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1C</xref>). Thus in both the testes and the retina (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>), only half the normal level of only a single TAM ligand (Pros1) is sufficient to maintain an essential level of TAM-dependent phagocytosis.</p><p>All three TAM receptors are detectable by western blot in the testis (<xref ref-type="fig" rid="fig8">Figure 8C</xref>), and there was no significant compensatory change in Tyro3, Axl, or Mer expression in <italic>Mertk</italic><sup><italic>−/−</italic></sup>, <italic>Tyro3</italic><sup><italic>−/−</italic></sup>, <italic>Gas6</italic><sup><italic>−/−</italic></sup>, or <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Gas6</italic><sup><italic>−/−</italic></sup> mice (<xref ref-type="fig" rid="fig8">Figure 8C</xref>). We used comparative signal intensities on Licor immunoblots of lysates from testis and TAM TKO MEFs expressing HA-tagged Tyro3, Axl, and Mer (<xref ref-type="fig" rid="fig8">Figure 8D</xref>) to determine that the relative protein expression level of TAM receptors in the testis is Mer &gt; Tyro3 &gt; Axl (<xref ref-type="fig" rid="fig8">Figure 8E</xref>). Finally, we confirmed that the phenotypes we analyzed at 10–12 weeks were fully developed by this time. We measured the number of cCasp3<sup>+</sup> cells in wild-type vs <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> mice at 10–12 weeks vs 9–12 months and saw that this number was the same in both the young and aged testis (<xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1D</xref>). Together, these results indicate that Mer is the major facilitator of steady-state homeostatic phagocytosis in both the retina and the testis, and that binding and activation of this receptor by Pros1 alone at only half its normal gene dose is sufficient to maintain normal levels of phagocytosis.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><sec id="s3-1"><title>TAM rules of engagement</title><p>From the above analyses, we draw seven salient conclusions with respect to TAM receptor–ligand–phospholipid interactions, which are summarized in <xref ref-type="fig" rid="fig9">Figure 9</xref>. First, Gas6 alone is capable of binding to and activating Tyro3, Axl, and Mer when these receptors are expressed in isolation and is especially potent as a ligand for Axl. Second, Pros1 alone is capable of binding to and activating Tyro3 and Mer but does not function as a ligand for Axl. Third, the PtdSer-binding Gla domain of Gas6, PtdSer itself, and calcium are all required for optimal receptor activation but none is required for receptor binding. Fourth, ligand binding does not translate into receptor activation: Gla-less Gas6 binds as well to Axl as does its full-length counterpart, but is dead as an activator, and full-length Gas6 binds to Axl in the presence of EDTA but does not activate. Fifth, receptor heterodimerization is not an essential feature of TAM activation, since the TAM receptors can be activated by purified single ligands when expressed as single receptors in MEFs in the absence of any other TAM receptor, and in the retina, Mer activation in wild-type and Tyro3-deficient RPE cells is equivalent. Sixth, in the two settings of PtdSer-dependent ‘homeostatic’ phagocytosis—by RPE cells in the adult retina and Sertoli cells in the adult testes—Mer is the functionally predominant TAM receptor. And seventh, in these settings, Pros1 binding to and activation of Mer alone is sufficient to ensure wild-type levels of phagocytosis.<fig id="fig9" position="float"><object-id pub-id-type="doi">10.7554/eLife.03385.016</object-id><label>Figure 9.</label><caption><title>Rules of engagement for TAM receptor ligand interaction and signaling.</title><p>Gas6 activates all three TAM receptors independently, but Axl is uniquely dependent on Gas6: Pros1 activates Tyro3 and Mer but not Axl. Optimal activation of any receptor by any ligand requires the simultaneous presence of PtdSer, which binds to the Gla domain of the ligands, and calcium ions (Ca<sup>2+</sup>). Gla-less Gas6 is dead as a ligand when assayed against Axl in isolation. Its Axl-bound orientation is schematized differently from Tyro3- and Mer-bound Gla-less Gas6, since the latter two result in partial kinase activation, although there are no structural data for these complexes. The right-most signaling configuration, in which full-length Gas6 is also inactive as an Axl ligand in the absence of PtdSer and Ca<sup>2+</sup>, is speculation based on the results of this paper and data in (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>). See text for details.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.03385.016">http://dx.doi.org/10.7554/eLife.03385.016</ext-link></p></caption><graphic xlink:href="elife-03385-fig9-v2.tif"/></fig></p><p>Prior to this study, the relative binding and selectivity of Gas6 and Pros1 to the individual TAM receptors were incompletely understood. While Gas6 was widely regarded as a universal TAM ligand, the role of Pros1 in TAM-mediated signaling has, until recently, been controversial (<xref ref-type="bibr" rid="bib22">Godowski et al., 1995</xref>; <xref ref-type="bibr" rid="bib74">Stitt et al., 1995</xref>; <xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>), and older data regarding the relative potency of Gas6 and Pros1 in the binding and activation of the specific TAM receptors in vitro were conflicting (<xref ref-type="bibr" rid="bib56">Ohashi et al., 1995</xref>; <xref ref-type="bibr" rid="bib50">Nagata et al., 1996</xref>; <xref ref-type="bibr" rid="bib10">Chen et al., 1997</xref>). Perhaps most importantly, all prior analyses of receptor activation following the addition of TAM ligands to cultured cells were confounded by the presence of endogenous TAM receptors in the cell lines used for these analyses. Together with earlier work from our group in the retina (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>), the studies of <xref ref-type="fig" rid="fig7 fig8">Figures 7 and 8</xref> represent the only use of molecular genetics to parse differential TAM receptor–ligand signaling interactions in vivo.</p></sec><sec id="s3-2"><title>A lipid-regulated, calcium-regulated kinase in which the lipid and calcium are both extracellular</title><p>Our experiments suggest a model in which the interaction between distinct TAM receptors and ligands defines a signaling signature that is specific for each ligand–receptor pair (<xref ref-type="fig" rid="fig9">Figure 9</xref>). This is best illustrated in the case of Gas6 activation of Axl, which is uniquely dependent on Gas6 for activation. Both full-length Gas6 and a Gla-less Gas6 variant that lacks its PtdSer-binding Gla domain bind to Axl with the same sub-nanomolar equilibrium dissociation constant, yet the former is an extremely potent Axl agonist while the latter is inactive, whether assayed in vitro or in vivo. Furthermore, full-length Gas6 cannot activate Axl in the presence of EDTA, which disrupts the binding of the Gas6 Gla domain to PtdSer. In a related study (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>), we have found that just as Axl is uniquely dependent on Gas6 for activation, so is Gas6 uniquely dependent on Axl for its stable localization in several different tissues in vivo. We find that Axl is constitutively pre-bound to Gas6 in these tissues but that this binding does not result in significant Axl activation (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>). Together, all of these observations suggest that the induced exposure of PtdSer is actually the regulated trigger for TAM activation and that the TAM receptor–ligand pair is in reality a PtdSer detector. They also suggest that a crystal structure of the two Ig-like domains of the Axl ectodomain bound to two molecules of Gla-less Gas6 (<xref ref-type="bibr" rid="bib65">Sasaki et al., 2006</xref>) reflects the structure of an inactive complex.</p><p>We propose that an effective TAM signaling complex in vivo is always tripartite, in that it is always composed of a TAM receptor, a Gla domain-containing TAM ligand, and the phospholipid PtdSer (<xref ref-type="fig" rid="fig9">Figure 9</xref>). This configuration is unique to the TAMs. In this regard, it is important to note that all settings of TAM-dependent ‘homeostatic phagocytosis’ are strictly co-dependent upon the exposure of PtdSer on the surface of the phagocytic target (<xref ref-type="bibr" rid="bib72">Shiratsuchi et al., 1997</xref>; <xref ref-type="bibr" rid="bib63">Ruggiero et al., 2012</xref>; <xref ref-type="bibr" rid="bib35">Lemke, 2013</xref>). In the case of RPE cell phagocytosis of juxtaposed PR outer segment tips, PtdSer is locally exposed only on these outer segment tips (i.e., not on the remainder of the photoreceptor) and only during the narrow window after subjective dawn in which phagocytosis occurs each day (<xref ref-type="bibr" rid="bib63">Ruggiero et al., 2012</xref>). The activity of Gla domains is also Ca<sup>2+</sup>-dependent, as these ions both stabilize the folded structure of the domain and also interact with PtdSer (<xref ref-type="bibr" rid="bib4">Bandyopadhyay, 2008</xref>; <xref ref-type="bibr" rid="bib28">Huang et al., 2009</xref>). Thus, the TAM receptor tyrosine kinases represent a novel addition to the set of enzymes, such as protein kinase C, whose activities are regulated by both calcium and lipid binding (<xref ref-type="bibr" rid="bib39">Lemmon, 2008</xref>; <xref ref-type="bibr" rid="bib40">Leonard and Hurley, 2011</xref>). The key difference for the TAMs is that neither the lipid nor the calcium binds the kinase directly. Instead, they bind the TAM ligands, which are outside the cell.</p></sec><sec id="s3-3"><title>Axl–Gas6 and inflammation</title><p>The dependence of Axl on Gas6 may be relevant to the fact that all of the very low level of Gas6 that is present in blood appears to be complexed with soluble Axl (sAxl) extracellular domain (<xref ref-type="bibr" rid="bib19">Ekman et al., 2010c</xref>). Upon Axl activation, this ‘ectodomain’ is proteolytically cleaved from the rest of the receptor (<xref ref-type="bibr" rid="bib12">Costa et al., 1996</xref>; <xref ref-type="bibr" rid="bib55">O'Bryan et al., 1995</xref>; <xref ref-type="bibr" rid="bib82">Wilhelm et al., 2008</xref>), which results in the generation of an sAxl–Gas6 complex. In related work, we have shown that this complex is also generated when Axl is activated in tissues subsequent to the injection of activating (cross-linking) α-Axl antibodies (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>). Although there are conflicting reports as to the presence of soluble Tyro3 and Mer ectodomains in serum and the possibility that Gas6 might also be bound to soluble Mer (<xref ref-type="bibr" rid="bib66">Sather et al., 2007</xref>; <xref ref-type="bibr" rid="bib19">Ekman et al., 2010c</xref>), antibody depletion of Gas6 from serum does not alter the gel filtration profile of either soluble Mer or Tyro3 (<xref ref-type="bibr" rid="bib19">Ekman et al., 2010c</xref>).</p><p>Elevated blood levels of soluble Axl have recently been reported to mark a variety of human disease and trauma states, including aortic aneurysm (<xref ref-type="bibr" rid="bib18">Ekman et al., 2010b</xref>), lupus flares (<xref ref-type="bibr" rid="bib87">Zhu et al., 2014</xref>), pneumonia infection (<xref ref-type="bibr" rid="bib31">Ko et al., 2014</xref>), preeclampsia (<xref ref-type="bibr" rid="bib41">Liu et al., 2014</xref>), coronary bypass (<xref ref-type="bibr" rid="bib34">Lee et al., 2013</xref>), obesity and insulin resistance (<xref ref-type="bibr" rid="bib26">Hsiao et al., 2013</xref>), and limb ischemia (<xref ref-type="bibr" rid="bib17">Ekman et al., 2010a</xref>). We suggest that the generation of a soluble Axl–Gas6 complex is triggered by the induced cellular exposure of PtdSer in many of these settings.</p></sec><sec id="s3-4"><title>Differential TAM activation in human disease</title><p>Aberrant TAM signaling in human disease, most notably in cancer, is now a major research focus (<xref ref-type="bibr" rid="bib33">Leconet et al., 2013</xref>; <xref ref-type="bibr" rid="bib48">Meyer et al., 2013</xref>; <xref ref-type="bibr" rid="bib67">Schlegel et al., 2013</xref>), and small-molecule TAM tyrosine kinase inhibitors and antibodies that inhibit TAM ligand–receptor binding are in development as cancer therapies (<xref ref-type="bibr" rid="bib24">Holland et al., 2010</xref>; <xref ref-type="bibr" rid="bib84">Ye et al., 2010</xref>; <xref ref-type="bibr" rid="bib6">Brandao et al., 2011</xref>; <xref ref-type="bibr" rid="bib67">Schlegel et al., 2013</xref>; <xref ref-type="bibr" rid="bib58">Paccez et al., 2014</xref>). These same inhibitors have been proposed for the treatment of enveloped virus infections (<xref ref-type="bibr" rid="bib5">Bhattacharyya et al., 2013</xref>; <xref ref-type="bibr" rid="bib70">Shibata et al., 2014</xref>). Conversely, TAM activators have been proposed as possible treatments for several autoimmune indications (<xref ref-type="bibr" rid="bib62">Rothlin and Lemke, 2010</xref>; <xref ref-type="bibr" rid="bib79">van den Brand et al., 2013</xref>).</p><p>In each of these settings, our results indicate that it will be critical to know which TAM receptor to target. This will be particularly important in the context of cancer, since tumors profiled in the TCGA database (<ext-link ext-link-type="uri" xlink:href="https://tcga-data.nci.nih.gov/tcga/">https://tcga-data.nci.nih.gov/tcga/</ext-link>) that exhibit mutation or expression changes in the <italic>Tyro3</italic>, <italic>Axl</italic>, and <italic>Mertk</italic> genes display a strong tendency towards mutually exclusive TAM changes across tumor types. At the same time, our studies here, related work in the immune system (<xref ref-type="bibr" rid="bib85">Zagórska et al., 2014</xref>), and prior analyses (<xref ref-type="bibr" rid="bib68">Scott et al., 2001</xref>; <xref ref-type="bibr" rid="bib61">Rothlin et al., 2007</xref>; <xref ref-type="bibr" rid="bib69">Seitz et al., 2007</xref>; <xref ref-type="bibr" rid="bib7">Burstyn-Cohen et al., 2009</xref>, <xref ref-type="bibr" rid="bib8">2012</xref>; <xref ref-type="bibr" rid="bib9">Carrera Silva et al., 2013</xref>) all demonstrate that distinct normal functions are preferentially assumed by individual TAM receptors and ligands in macrophages, dendritic cells, Sertoli cells, endothelial cells, and RPE cells. Our delineation of the rules of engagement for TAM signaling (<xref ref-type="fig" rid="fig9">Figure 9</xref>) therefore has important implications for the therapeutic application of inhibiting and activating TAM modulators, particularly with respect to their target specificity and the avoidance of possible treatment side effects in the immune, visual, and reproductive systems.</p></sec></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Antibodies and reagents</title><p>Antibodies used were as follows: anti-Tyro3 (Santa Cruz, Dallas, TX, sc-1095, R&amp;D Systems, Minneapolis, MN, AF759), anti-Axl (Santa Cruz sc-1097, R&amp;D Systems AF854), anti-Mer (R&amp;D Systems AF591), anti-HA (Covance, Princeton, NJ, MMS-101P, Roche, Mannheim, Germany 11 867 423 001), anti-Gas6 (R&amp;D Systems AF986), anti-Akt (Cell Signaling, Beverly, MA, 4691), anti-Gapdh (Millipore, Billerica, MA, MAB374), anti-cleaved caspase 3 (Cell Signaling 9661), and anti-phosphotyrosine (Millipore 05–321). Human Pros1 was from Enzyme Research Laboratories, South Bend, IN, and Tet-Express from Clontech, Mountain View, CA.</p></sec><sec id="s4-2"><title>Mice</title><p>Mice were bred and housed in the Salk Institute Animal Facility in a sterile environment under a 12-hr light/dark cycle. All experiments and procedures were conducted according to the guidelines established by the Institutional Animal Care and Use Committee (IACUC). The <italic>Tyro3</italic><sup><italic>−/−</italic></sup>, <italic>Axl</italic><sup><italic>−/−</italic></sup>, and <italic>Mertk</italic><sup><italic>−/−</italic></sup> mutants (<xref ref-type="bibr" rid="bib42">Lu et al., 1999</xref>), the <italic>Gas6</italic><sup><italic>−/−</italic></sup> mutants (<xref ref-type="bibr" rid="bib2">Angelillo-Scherrer et al., 2001</xref>), and the floxed <italic>Pros1</italic> mutants (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>) were all as described previously. All mice used in this paper were on a pure C57Bl/6 background, with two exceptions: the <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Axl</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> (TAM TKO) triple mutant mice of <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1A</xref> and the young/old comparison of <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1B,D</xref>, both of which were on a mixed C57Bl/6 × 129sv background.</p></sec><sec id="s4-3"><title>Generation of cell lines</title><p>Spontaneously immortalized MEF cell lines from <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Axl</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> and <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Mertk</italic><sup><italic>−/−</italic></sup> mutant mice were generated following a standard 3T3 protocol (<xref ref-type="bibr" rid="bib83">Xu, 2005</xref>). Briefly, E13.5–15.5 embryos were isolated from a pregnant female of each genotype, and embryo body was subject to manual dissociation and incubation with trypsin to isolate single cells. Proliferation of isolated cells was monitored for 15–25 passages, and a growth curve was calculated for each cell passage. Immortalized MEFs were subsequently frozen and utilized for experiments.</p><p>C-terminal HA-tagged Tyro3 or Axl cDNA was sub-cloned into pMX IRES retroviral vector. Retrovirus was produced in Phoenix Ampho cell lines and used to transduce TAM TKO cells. For Tet-inducible Mer cell lines, C-terminal HA-tagged Mertk cDNA was sub-cloned into a pRetroX-Tre3G vector and co-transfected with pAmpho env expression vector into a GP2-293 cell for retrovirus production according the manufacturer's protocol (Clontech). Clonal populations were generated following antibiotic selection and receptor levels normalized by quantitative immunoblotting using the HA tag.</p></sec><sec id="s4-4"><title>Generation and purification of recombinant TAM ligands</title><p>cDNAs encoding either full-length mouse Gas6/Pros1 or Gas6/Pros1 lacking the Gla domain were sub-cloned into pCep4 vector (Invitrogen, Carlsbad, CA). PCR primers introduced a C-terminal His<sub>6</sub> tag for purification and the constructs were transfected into HEK293 cells. Cells were grown to confluency in DMEM supplemented with 10% FBS, 0.25 mg/ml G418, 100 µg/ml hygromycin, and Pen/Strep and subsequently switched to serum-free Pro CDMa medium (Lonza, Walkersville, MD) supplemented with 10 µM vitamin K2 (Sigma, St. Louis, MO) and Pen/Strep for 72 hr. Conditioned medium was passed through a 0.22 µm filter, affinity purified through a nickel-NTA resin, and further purified on an anion exchange column (Mono Q 5/5; GE Healthcare, Pittsburgh, PA) in 20 mM Tris–HCl, pH 8.0 using a sodium chloride gradient.</p></sec><sec id="s4-5"><title><sup>125</sup>I-rmGas6 binding assays</title><p>Recombinant full-length mouse Gas6 was <sup>125</sup>I-labeled by the iodogen method according to the manufacturer's protocol (Pierce, Rockford, IL). Immortalized <italic>Tyro3</italic><sup><italic>−/−</italic></sup><italic>Mer</italic><sup><italic>−/−</italic></sup> MEFs were plated in a 12-well dish in triplicate and subsequently pre-starved in 3% FBS in DMEM overnight until cells reach confluency. Cells were placed in starvation medium for 3 hr before binding assays were performed. For binding experiments, cells were incubated with <sup>125</sup>I-labeled full-length rmGas6 with increasing concentrations of either unlabeled full-length rmGas6 or unlabeled Gla-less Gas6 for 3 hr on ice. Cells were washed and subsequently lysed overnight in 0.5 M NaOH. Radioactive content of the cell lysates was counted in Opti-Fluor (Perkin Elmer, Waltham, MA) using a scintillation counter (Beckman Coulter, Brea, CA, LS6500). The half-life of the displacement curves was determined by fitting the curve with Prism software (Graphpad).</p></sec><sec id="s4-6"><title>Immunocytochemistry</title><p>Cells were plated on glass coverslips, pre-starved overnight in 3% FBS/DMEM, and subsequently incubated in serum-free medium for 3 hr prior to treatment. Coverslips were briefly washed with 1× PBS, fixed for 15 min with 4% paraformaldehyde (PFA)/PBS, incubated in blocking buffer (3% BSA/0.05% saponin/PBS), primary antibody, and fluorophore-conjugated secondary antibody diluted in blocking buffer. For live labeling for surface receptor expression (<xref ref-type="fig" rid="fig1">Figure 1B</xref> and <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>), coverslips were transferred to chilled serum-free cell culture medium supplemented with anti-Tyro3 or anti-Axl antibodies (R&amp;D Systems) on ice for 30 min. Coverslips were briefly washed with ice cold PBS, fixed for 15 min in 4% PFA/PBS, incubated with a fluorophore-conjugated secondary antibody, and counterstained with Hoechst solution. For live labeling for Gas6 binding assays (<xref ref-type="fig" rid="fig4">Figure 4D</xref>), coverslips were transferred to chilled serum-free cell culture medium with and without TAM ligand or EDTA, respectively, at 4°C for 90 min. Coverslips were briefly washed with ice cold PBS, fixed for 15 min in 4% PFA/PBS, and incubated with primary antibody, fluorophore-conjugated secondary antibody, and counterstained with Hoechst solution. Following washing with 0.1% Tween-20/PBS, coverslips were mounted using Fluoromount G (Electron Microscopy Sciences) and visualized with a Zeiss LSM 710 Laser Scanning Confocal Microscope.</p></sec><sec id="s4-7"><title>Tissue culture, immunoprecipitation, and western blotting</title><p>MEFs were grown in Dulbecco's Modified Eagle's Medium supplemented with 10% FBS, and Pen/Strep, and selection antibiotic. Prior to stimulation with ligand, cells were pre-starved overnight in DMEM supplemented with 3% FBS and Pen/Strep and subsequently incubated in starvation conditions for 3 hr.</p><p>For BMDM cultures, bone marrow was isolated from tibiae and femurs of 6- to 12-week old C57Bl/6 mice according to the guidelines of the International Animal Care and Use Committee (IACUC). Bones were flushed with DMEM supplemented with 10% FBS and Pen/Strep, spun down at 350 × <italic>g</italic> for 6 min, incubated with ACK lysis buffer for 1 min, and hematopoietic progenitors incubated with DMEM supplemented with 10% FBS, 30% L929 conditioned medium, Pen/Strep, and glutamax. Cells were supplemented with fresh medium on day 3 and cells re-plated on day 7 in DMEM supplemented with 10% FBS and Pen/Strep for experiments. For activation assays, cells were placed under starvation conditions supplemented with 100 nM dexamethasone and Pen/Strep overnight.</p><p>Following stimulation with TAM ligands at the indicated concentrations and time periods, cells were washed in PBS and lysed in lysis buffer [50 mM HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 10% glycerol, 1% Triton X-100, 25 mM NaF, 10 µM ZnCl<sub>2</sub>, and protease and phosphatase inhibitors (Roche, Sigma)] for 30 min on ice. For immunoprecipitation, cell lysates were incubated with anti-HA high affinity (Roche), anti-Mer (R&amp;D System), or anti-Tyro3 (Santa Cruz) antibodies, and either protein A/protein G-Sepharose conjugated beads (Life Technologies). Immunoprecipitates were washed 4× with HNTG buffer (20 mM HEPES, pH 7.5, 150 mM NaCl, 0.1% Triton X, 10% glycerol, 1 mM Na<sub>3</sub>VO<sub>4</sub>), separated by SDS-PAGE, transferred to PVDF membrane (Millipore), incubated with primary antibodies in blocking buffer (1% casein block in PBS) (Biorad), and western blots were developed using an Odyssey Gel Imaging System (Licor).</p></sec><sec id="s4-8"><title>Histology and immunohistochemistry</title><p>Mice were collected at 12–14 weeks and were anesthetized with 2.5% avertin in saline. Mice were perfused with 20 U/ml heparin/PBS and subsequently with 4% PFA in PBS. Eyes were processed as previously described (<xref ref-type="bibr" rid="bib8">Burstyn-Cohen et al., 2012</xref>). Testes were collected, immersion fixed overnight at 4°C, infiltrated with 30% sucrose/PBS overnight at 4°C, and flash frozen in TBS tissue freezing medium. 10 µm serial sections were cut for light microscopy studies and immunohistochemistry, respectively. Sections were air dried overnight at room temperature and subsequently frozen at −80°C.</p><p>For cCasp3 staining, sections were washed in PBS, incubated in 0.3% H<sub>2</sub>O<sub>2</sub> in PBS to block endogenous peroxidase activity, blocked in 3% BSA in PBS, and incubated in anti-cCasp3 (Cell Signaling) diluted in blocking buffer. DAB staining was performed with an ABC Vectastain Kit (Vector Labs) and Peroxidase Substrate Staining Kit (Vector Labs). Following washing steps in PBS + 0.1% Tween-20, slides were counterstained with hematoxylin for 1 min and mounted using VectaMount (Vector Labs). For quantitation, cCasp3-positive cells and tubule numbers from four testis cross-sections per animal were counted and averaged per animal. Error bars represent standard error of the mean from three independent animals.</p></sec><sec id="s4-9"><title>Flow cytometry</title><p>Cells were plated in 6-cm dishes and when cells reached confluency, they were pre-starved in 3% FBS/DMEM overnight and then incubated in starvation medium for 3 hr before experiment. Supernatant was collected for analysis, and adherent cells were washed with PBS, incubated with 0.25% trypsin briefly, and collected in FACS buffer (0.5% BSA/0.1% Na azide/PBS supplemented with either 2 mM CaCl2 or 10 mM EDTA). Supernatant and cell samples were incubated with pSiva-IANBD and Propidium iodide (PI) (Imgenex) for 30 min on ice. Samples were sorted on a Becton-Dickinson LSR II (Salk Institute Flow Cytometry Core Facility) and data analyzed using FloJo software (Treestar).</p></sec><sec id="s4-10"><title>Gas6 injections in vivo</title><p>Male and female 13- to 15-week old mice were injected intravenously (retro-orbital injection, 100 μl final volume) with 30 μg full-length recombinant mouse Gas6 (in saline), Gla-less recombinant Gas6, or saline as a control. Mice were sacrificed at 30 min post-injection and the spleens split in half: one half was snap frozen for biochemical analysis and the second half was fresh frozen in OCT freezing medium, as indicated in <xref ref-type="fig" rid="fig5">Figure 5</xref>.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>We thank Joseph Hash for excellent technical support and members of the Lemke and Schlessinger labs for helpful discussions. This work was supported by grants from the National Institutes of Health (R01 AI077058, R01 AI101400, and R01 NS085296 to GL, and P30CA014195 to the Salk Institute) and the Leona M and Harry B Helmsley Charitable Trust (#2012-PG-MED002 to the Salk Institute), by the Nomis, H N and Frances C Berger, Fritz B Burns, and HKT Foundations, by Frederik Paulson and Françoise Gilot-Salk, and by post-doctoral fellowships from the Leukemia and Lymphoma Society and the Nomis Foundation (to EDL), the Human Frontiers Science Program (to AZ), and the Marie Curie International Outgoing Fellowship Program (to PGT).</p></ack><sec sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>IL: is a shareholder in Kolltan Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf2"><p>JS: is a shareholder in Kolltan Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf3"><p>GL: is a shareholder in Kolltan Pharmaceuticals.</p></fn><fn fn-type="conflict" id="conf4"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>EDL, Conception and design, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>JO, Conception and design, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con3"><p>PGB, Conception and design, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con4"><p>IL, Conception and design, Acquisition of data, Analysis and interpretation of data</p></fn><fn fn-type="con" id="con5"><p>AZ, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>PGT, Acquisition of data, Analysis and interpretation of data, Drafting or revising the article</p></fn><fn fn-type="con" id="con7"><p>JS, Conception and design, Drafting or revising the article, Contributed unpublished essential data or reagents</p></fn><fn fn-type="con" id="con8"><p>GL, Conception and design, Analysis and interpretation of data, Drafting or revising the article</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved Institutional Animal Care and Use Committee (IACUC) protocol of the Salk Institute, Animal Use Protocol No. 11-00051, approval date of record 3 June 2014.</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>HA</given-names></name><name><surname>Maylock</surname><given-names>CA</given-names></name><name><surname>Williams</surname><given-names>JA</given-names></name><name><surname>Paweletz</surname><given-names>CP</given-names></name><name><surname>Shu</surname><given-names>H</given-names></name><name><surname>Shacter</surname><given-names>E</given-names></name></person-group><year>2003</year><article-title>Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells</article-title><source>Nature Immunology</source><volume>4</volume><fpage>87</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1038/ni871</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Angelillo-Scherrer</surname><given-names>A</given-names></name><name><surname>de Frutos</surname><given-names>P</given-names></name><name><surname>Aparicio</surname><given-names>C</given-names></name><name><surname>Melis</surname><given-names>E</given-names></name><name><surname>Savi</surname><given-names>P</given-names></name><name><surname>Lupu</surname><given-names>F</given-names></name><name><surname>Arnout</surname><given-names>J</given-names></name><name><surname>Dewerchin</surname><given-names>M</given-names></name><name><surname>Hoylaerts</surname><given-names>M</given-names></name><name><surname>Herbert</surname><given-names>J</given-names></name><name><surname>Collen</surname><given-names>D</given-names></name><name><surname>Dahlbäck</surname><given-names>B</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name></person-group><year>2001</year><article-title>Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis</article-title><source>Nature Medicine</source><volume>7</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/84667</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Avilla</surname><given-names>E</given-names></name><name><surname>Guarino</surname><given-names>V</given-names></name><name><surname>Visciano</surname><given-names>C</given-names></name><name><surname>Liotti</surname><given-names>F</given-names></name><name><surname>Svelto</surname><given-names>M</given-names></name><name><surname>Krishnamoorthy</surname><given-names>G</given-names></name><name><surname>Franco</surname><given-names>R</given-names></name><name><surname>Melillo</surname><given-names>RM</given-names></name></person-group><year>2011</year><article-title>Activation of TYRO3/AXL tyrosine kinase receptors in thyroid cancer</article-title><source>Cancer Research</source><volume>71</volume><fpage>1792</fpage><lpage>1804</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-2186</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bandyopadhyay</surname><given-names>PK</given-names></name></person-group><year>2008</year><article-title>Vitamin K-dependent gamma-glutamylcarboxylation: an ancient posttranslational modification</article-title><source>Vitamins and Hormones</source><volume>78</volume><fpage>157</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1016/S0083-6729(07)00008-8</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhattacharyya</surname><given-names>S</given-names></name><name><surname>Zagorska</surname><given-names>A</given-names></name><name><surname>Lew</surname><given-names>ED</given-names></name><name><surname>Shrestha</surname><given-names>B</given-names></name><name><surname>Rothlin</surname><given-names>CV</given-names></name><name><surname>Naughton</surname><given-names>J</given-names></name><name><surname>Diamond</surname><given-names>MS</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Young</surname><given-names>JA</given-names></name></person-group><year>2013</year><article-title>Enveloped viruses disable innate immune responses in dendritic cells by direct activation of TAM receptors</article-title><source>Cell Host &amp; Microbe</source><volume>14</volume><fpage>136</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2013.07.005</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brandao</surname><given-names>L</given-names></name><name><surname>Migdall-Wilson</surname><given-names>J</given-names></name><name><surname>Eisenman</surname><given-names>K</given-names></name><name><surname>Graham</surname><given-names>DK</given-names></name></person-group><year>2011</year><article-title>TAM receptors in leukemia: expression, signaling, and therapeutic implications</article-title><source>Critical Reviews in Oncogenesis</source><volume>16</volume><fpage>47</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1615/CritRevOncog.v16.i1-2.60</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstyn-Cohen</surname><given-names>T</given-names></name><name><surname>Heeb</surname><given-names>MJ</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2009</year><article-title>Lack of protein S in mice causes embryonic lethal coagulopathy and vascular dysgenesis</article-title><source>The Journal of Clinical Investigation</source><volume>119</volume><fpage>2942</fpage><lpage>2953</lpage><pub-id pub-id-type="doi">10.1172/JCI39325</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Burstyn-Cohen</surname><given-names>T</given-names></name><name><surname>Lew</surname><given-names>ED</given-names></name><name><surname>Traves</surname><given-names>PG</given-names></name><name><surname>Burrola</surname><given-names>PG</given-names></name><name><surname>Hash</surname><given-names>JC</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2012</year><article-title>Genetic dissection of TAM receptor-ligand interaction in retinal pigment epithelial cell phagocytosis</article-title><source>Neuron</source><volume>76</volume><fpage>1123</fpage><lpage>1132</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2012.10.015</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrera Silva</surname><given-names>EA</given-names></name><name><surname>Chan</surname><given-names>PY</given-names></name><name><surname>Joannas</surname><given-names>L</given-names></name><name><surname>Errasti</surname><given-names>AE</given-names></name><name><surname>Gagliani</surname><given-names>N</given-names></name><name><surname>Bosurgi</surname><given-names>L</given-names></name><name><surname>Jabbour</surname><given-names>M</given-names></name><name><surname>Perry</surname><given-names>A</given-names></name><name><surname>Smith-Chakmakova</surname><given-names>F</given-names></name><name><surname>Mucida</surname><given-names>D</given-names></name><name><surname>Cheroutre</surname><given-names>H</given-names></name><name><surname>Burstyn-Cohen</surname><given-names>T</given-names></name><name><surname>Leighton</surname><given-names>JA</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Rothlin</surname><given-names>CV</given-names></name></person-group><year>2013</year><article-title>T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response</article-title><source>Immunity</source><volume>39</volume><fpage>160</fpage><lpage>170</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.06.010</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Carey</surname><given-names>K</given-names></name><name><surname>Godowski</surname><given-names>PJ</given-names></name></person-group><year>1997</year><article-title>Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation</article-title><source>Oncogene</source><volume>14</volume><fpage>2033</fpage><lpage>2039</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1201039</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Qi</surname><given-names>N</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>D</given-names></name></person-group><year>2009</year><article-title>Functions of TAM RTKs in regulating spermatogenesis and male fertility in mice</article-title><source>Reproduction</source><volume>138</volume><fpage>655</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1530/REP-09-0101</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>M</given-names></name><name><surname>Bellosta</surname><given-names>P</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name></person-group><year>1996</year><article-title>Cleavage and release of a soluble form of the receptor tyrosine kinase ARK in vitro and in vivo</article-title><source>Journal of Cellular Physiology</source><volume>168</volume><fpage>737</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1097-4652(199609)168:33.0.CO;2-U</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>CT</given-names></name><name><surname>Deryckere</surname><given-names>D</given-names></name><name><surname>Earp</surname><given-names>HS</given-names></name><name><surname>Graham</surname><given-names>DK</given-names></name></person-group><year>2013</year><article-title>Molecular pathways: MERTK signaling in cancer</article-title><source>Clinical Cancer Research</source><volume>19</volume><fpage>5275</fpage><lpage>5280</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-12-1451</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Cruz</surname><given-names>PM</given-names></name><name><surname>Yasumura</surname><given-names>D</given-names></name><name><surname>Weir</surname><given-names>J</given-names></name><name><surname>Matthes</surname><given-names>MT</given-names></name><name><surname>Abderrahim</surname><given-names>H</given-names></name><name><surname>LaVail</surname><given-names>MM</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name></person-group><year>2000</year><article-title>Mutation of the receptor tyrosine kinase gene Mertk in the retinal dystrophic RCS rat</article-title><source>Human Molecular Genetics</source><volume>9</volume><fpage>645</fpage><lpage>651</lpage><pub-id pub-id-type="doi">10.1093/hmg/9.4.645</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demarest</surname><given-names>SJ</given-names></name><name><surname>Gardner</surname><given-names>J</given-names></name><name><surname>Vendel</surname><given-names>MC</given-names></name><name><surname>Ailor</surname><given-names>E</given-names></name><name><surname>Szak</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>F</given-names></name><name><surname>Doern</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>W</given-names></name><name><surname>Grueneberg</surname><given-names>DA</given-names></name><name><surname>Richards</surname><given-names>EJ</given-names></name><name><surname>Endege</surname><given-names>WO</given-names></name><name><surname>Harlow</surname><given-names>E</given-names></name><name><surname>Koopman</surname><given-names>LA</given-names></name></person-group><year>2013</year><article-title>Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines</article-title><source>Biochemistry</source><volume>52</volume><fpage>3102</fpage><lpage>3118</lpage><pub-id pub-id-type="doi">10.1021/bi301588c</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duncan</surname><given-names>HJ</given-names></name><name><surname>LaVail</surname><given-names>MM</given-names></name><name><surname>Yasumura</surname><given-names>D</given-names></name><name><surname>Matthes</surname><given-names>MT</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Trautmann</surname><given-names>N</given-names></name><name><surname>Chappelow</surname><given-names>AV</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Earp</surname><given-names>HS</given-names></name><name><surname>Matsushima</surname><given-names>GK</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name></person-group><year>2003</year><article-title>An RCS-like retinal dystrophy phenotype in mer knockout mice</article-title><source>Investigative Ophthalmology &amp; Visual Science</source><volume>44</volume><fpage>826</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1167/iovs.02-0438</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekman</surname><given-names>C</given-names></name><name><surname>Gottsater</surname><given-names>A</given-names></name><name><surname>Lindblad</surname><given-names>B</given-names></name><name><surname>Dahlback</surname><given-names>B</given-names></name></person-group><year>2010a</year><article-title>Plasma concentrations of Gas6 and soluble Axl correlate with disease and predict mortality in patients with critical limb ischemia</article-title><source>Clinical Biochemistry</source><volume>43</volume><fpage>873</fpage><lpage>876</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2010.04.006</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekman</surname><given-names>C</given-names></name><name><surname>Site</surname><given-names>DF</given-names></name><name><surname>Gottsater</surname><given-names>A</given-names></name><name><surname>Lindblad</surname><given-names>B</given-names></name><name><surname>Dahlback</surname><given-names>B</given-names></name></person-group><year>2010b</year><article-title>Plasma concentrations of growth arrest specific protein 6 and the soluble form of its tyrosine kinase receptor Axl as markers of large abdominal aortic aneurysms</article-title><source>Clinical Biochemistry</source><volume>43</volume><fpage>110</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2009.07.025</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ekman</surname><given-names>C</given-names></name><name><surname>Stenhoff</surname><given-names>J</given-names></name><name><surname>Dahlback</surname><given-names>B</given-names></name></person-group><year>2010c</year><article-title>Gas6 is complexed to the soluble tyrosine kinase receptor Axl in human blood</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>8</volume><fpage>838</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2010.03752.x</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Freedman</surname><given-names>SJ</given-names></name><name><surname>Furie</surname><given-names>BC</given-names></name><name><surname>Furie</surname><given-names>B</given-names></name><name><surname>Baleja</surname><given-names>JD</given-names></name></person-group><year>1995</year><article-title>Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX</article-title><source>Biochemistry</source><volume>34</volume><fpage>12126</fpage><lpage>12137</lpage><pub-id pub-id-type="doi">10.1021/bi00038a005</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gal</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Thompson</surname><given-names>DA</given-names></name><name><surname>Weir</surname><given-names>J</given-names></name><name><surname>Orth</surname><given-names>U</given-names></name><name><surname>Jacobson</surname><given-names>SG</given-names></name><name><surname>Apfelstedt-Sylla</surname><given-names>E</given-names></name><name><surname>Vollrath</surname><given-names>D</given-names></name></person-group><year>2000</year><article-title>Mutations in MERTK, the human orthologue of the RCS rat retinal dystrophy gene, cause retinitis pigmentosa</article-title><source>Nature Genetics</source><volume>26</volume><fpage>270</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/81555</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Godowski</surname><given-names>PJ</given-names></name><name><surname>Mark</surname><given-names>MR</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Sadick</surname><given-names>MD</given-names></name><name><surname>Raab</surname><given-names>H</given-names></name><name><surname>Hammonds</surname><given-names>RG</given-names></name></person-group><year>1995</year><article-title>Reevaluation of the roles of protein S and Gas6 as ligands for the receptor tyrosine kinase Rse/Tyro 3</article-title><source>Cell</source><volume>82</volume><fpage>355</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90424-7</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hafizi</surname><given-names>S</given-names></name><name><surname>Dahlback</surname><given-names>B</given-names></name></person-group><year>2006</year><article-title>Gas6 and protein S. Vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily</article-title><source>The FEBS Journal</source><volume>273</volume><fpage>5231</fpage><lpage>5244</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2006.05529.x</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holland</surname><given-names>SJ</given-names></name><name><surname>Pan</surname><given-names>A</given-names></name><name><surname>Franci</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Duan</surname><given-names>M</given-names></name><name><surname>Torneros</surname><given-names>A</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Heckrodt</surname><given-names>TJ</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ding</surname><given-names>P</given-names></name><name><surname>Apatira</surname><given-names>A</given-names></name><name><surname>Chua</surname><given-names>J</given-names></name><name><surname>Brandt</surname><given-names>R</given-names></name><name><surname>Pine</surname><given-names>P</given-names></name><name><surname>Goff</surname><given-names>D</given-names></name><name><surname>Singh</surname><given-names>R</given-names></name><name><surname>Payan</surname><given-names>DG</given-names></name><name><surname>Hitoshi</surname><given-names>Y</given-names></name></person-group><year>2010</year><article-title>R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</article-title><source>Cancer Research</source><volume>70</volume><fpage>1544</fpage><lpage>1554</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-09-2997</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>CC</given-names></name><name><surname>Lay</surname><given-names>JD</given-names></name><name><surname>Huang</surname><given-names>JS</given-names></name><name><surname>Cheng</surname><given-names>AL</given-names></name><name><surname>Tang</surname><given-names>JL</given-names></name><name><surname>Lin</surname><given-names>MT</given-names></name><name><surname>Lai</surname><given-names>GM</given-names></name><name><surname>Chuang</surname><given-names>SE</given-names></name></person-group><year>2008</year><article-title>Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</article-title><source>Cancer Letters</source><volume>268</volume><fpage>314</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.04.017</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsiao</surname><given-names>FC</given-names></name><name><surname>Lin</surname><given-names>YF</given-names></name><name><surname>Hsieh</surname><given-names>PS</given-names></name><name><surname>Chu</surname><given-names>NF</given-names></name><name><surname>Shieh</surname><given-names>YS</given-names></name><name><surname>Hsieh</surname><given-names>CH</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Hung</surname><given-names>YJ</given-names></name></person-group><year>2013</year><article-title>Circulating growth arrest-specific 6 protein is associated with adiposity, systemic inflammation, and insulin resistance among overweight and obese adolescents</article-title><source>The Journal of Clinical Endocrinology and Metabolism</source><volume>98</volume><fpage>E267</fpage><lpage>E274</lpage><pub-id pub-id-type="doi">10.1210/jc.2012-3179</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>M</given-names></name><name><surname>Rigby</surname><given-names>AC</given-names></name><name><surname>Morelli</surname><given-names>X</given-names></name><name><surname>Grant</surname><given-names>MA</given-names></name><name><surname>Huang</surname><given-names>G</given-names></name><name><surname>Furie</surname><given-names>B</given-names></name><name><surname>Seaton</surname><given-names>B</given-names></name><name><surname>Furie</surname><given-names>BC</given-names></name></person-group><year>2003</year><article-title>Structural basis of membrane binding by Gla domains of vitamin K-dependent proteins</article-title><source>Nature Structural Biology</source><volume>10</volume><fpage>751</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1038/nsb971</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Finerty</surname><given-names>P</given-names><suffix>Jnr</suffix></name><name><surname>Walker</surname><given-names>JR</given-names></name><name><surname>Butler-Cole</surname><given-names>C</given-names></name><name><surname>Vedadi</surname><given-names>M</given-names></name><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>SA</given-names></name><name><surname>Turk</surname><given-names>BE</given-names></name><name><surname>Thompson</surname><given-names>DA</given-names></name><name><surname>Dhe-Paganon</surname><given-names>S</given-names></name></person-group><year>2009</year><article-title>Structural insights into the inhibited states of the Mer receptor tyrosine kinase</article-title><source>Journal of Structural Biology</source><volume>165</volume><fpage>88</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/j.jsb.2008.10.003</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimoto</surname><given-names>Y</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name></person-group><year>2000</year><article-title>Promotion of the uptake of PS liposomes and apoptotic cells by a product of growth arrest-specific gene, gas6</article-title><source>Journal of Biochemistry</source><volume>127</volume><fpage>411</fpage><lpage>417</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.jbchem.a022622</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YE</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>JR</given-names></name><name><surname>Langen</surname><given-names>R</given-names></name></person-group><year>2010</year><article-title>Engineering a polarity-sensitive biosensor for time-lapse imaging of apoptotic processes and degeneration</article-title><source>Nature Methods</source><volume>7</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1038/nmeth.1405</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>CP</given-names></name><name><surname>Yu</surname><given-names>YL</given-names></name><name><surname>Hsiao</surname><given-names>PC</given-names></name><name><surname>Yang</surname><given-names>SF</given-names></name><name><surname>Yeh</surname><given-names>CB</given-names></name></person-group><year>2014</year><article-title>Plasma levels of soluble Axl correlate with severity of community-acquired pneumonia</article-title><source>Molecular Medicine Reports</source><volume>9</volume><fpage>1400</fpage><lpage>1404</lpage><pub-id pub-id-type="doi">10.3892/mmr.2014.1933</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>R</given-names></name><name><surname>Dignat-George</surname><given-names>F</given-names></name></person-group><year>2012</year><article-title>Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulation</article-title><source>Thrombosis Research</source><volume>129</volume><supplement>Suppl 2</supplement><fpage>S27</fpage><lpage>S29</lpage><pub-id pub-id-type="doi">10.1016/j.thromres.2012.02.025</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leconet</surname><given-names>W</given-names></name><name><surname>Larbouret</surname><given-names>C</given-names></name><name><surname>Chardes</surname><given-names>T</given-names></name><name><surname>Thomas</surname><given-names>G</given-names></name><name><surname>Neiveyans</surname><given-names>M</given-names></name><name><surname>Busson</surname><given-names>M</given-names></name><name><surname>Jarlier</surname><given-names>M</given-names></name><name><surname>Radosevic-Robin</surname><given-names>N</given-names></name><name><surname>Pugniere</surname><given-names>M</given-names></name><name><surname>Bernex</surname><given-names>F</given-names></name><name><surname>Penault-Llorca</surname><given-names>F</given-names></name><name><surname>Pasquet</surname><given-names>JM</given-names></name><name><surname>Pèlegrin</surname><given-names>A</given-names></name><name><surname>Robert</surname><given-names>B</given-names></name></person-group><year>2013</year><article-title>Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy</article-title><source>Oncogene</source><pub-id pub-id-type="doi">10.1038/onc.2013.487</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Shieh</surname><given-names>YS</given-names></name><name><surname>Tsai</surname><given-names>CS</given-names></name><name><surname>Hung</surname><given-names>YJ</given-names></name><name><surname>Tsai</surname><given-names>YT</given-names></name><name><surname>Lin</surname><given-names>CY</given-names></name></person-group><year>2013</year><article-title>Plasma concentrations predict aortic expression of growth-arrest-specific protein 6 in patients undergoing coronary artery bypass grafting</article-title><source>PLOS ONE</source><volume>8</volume><fpage>e79452</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0079452</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2013</year><article-title>Biology of the TAM receptors</article-title><source>Cold Spring Harbor Perspectives in Biology</source><volume>5</volume><fpage>a009076</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a009076</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Burstyn-Cohen</surname><given-names>T</given-names></name></person-group><year>2010</year><article-title>TAM receptors and the clearance of apoptotic cells</article-title><source>Annals of the New York Academy of Sciences</source><volume>1209</volume><fpage>23</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2010.05744.x</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name></person-group><year>2003</year><article-title>Macrophage regulation by Tyro 3 family receptors</article-title><source>Current Opinion in Immunology</source><volume>15</volume><fpage>31</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/S0952-7915(02)00016-X</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Rothlin</surname><given-names>CV</given-names></name></person-group><year>2008</year><article-title>Immunobiology of the TAM receptors</article-title><source>Nature Reviews Immunology</source><volume>8</volume><fpage>327</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/nri2303</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lemmon</surname><given-names>MA</given-names></name></person-group><year>2008</year><article-title>Membrane recognition by phospholipid-binding domains</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>9</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/nrm2328</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leonard</surname><given-names>TA</given-names></name><name><surname>Hurley</surname><given-names>JH</given-names></name></person-group><year>2011</year><article-title>Regulation of protein kinases by lipids</article-title><source>Current Opinion in Structural Biology</source><volume>21</volume><fpage>785</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2011.07.006</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Gui</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name></person-group><year>2014</year><article-title>Plasma concentrations of sAxl are associated with severe preeclampsia</article-title><source>Clinical Biochemistry</source><volume>47</volume><fpage>173</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.clinbiochem.2013.11.001</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Camenisch</surname><given-names>T</given-names></name><name><surname>Boast</surname><given-names>S</given-names></name><name><surname>Casagranda</surname><given-names>F</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Skinner</surname><given-names>MK</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Matsushima</surname><given-names>GK</given-names></name><name><surname>Earp</surname><given-names>HS</given-names></name><name><surname>Goff</surname><given-names>SP</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>1999</year><article-title>Tyro-3 family receptors are essential regulators of mammalian spermatogenesis</article-title><source>Nature</source><volume>398</volume><fpage>723</fpage><lpage>728</lpage><pub-id pub-id-type="doi">10.1038/19554</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2001</year><article-title>Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</article-title><source>Science</source><volume>293</volume><fpage>306</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1126/science.1061663</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mackay</surname><given-names>DS</given-names></name><name><surname>Henderson</surname><given-names>RH</given-names></name><name><surname>Sergouniotis</surname><given-names>PI</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Moradi</surname><given-names>P</given-names></name><name><surname>Holder</surname><given-names>GE</given-names></name><name><surname>Waseem</surname><given-names>N</given-names></name><name><surname>Bhattacharya</surname><given-names>SS</given-names></name><name><surname>Aldahmesh</surname><given-names>MA</given-names></name><name><surname>Alkuraya</surname><given-names>FS</given-names></name><name><surname>Meyer</surname><given-names>B</given-names></name><name><surname>Webster</surname><given-names>AR</given-names></name><name><surname>Moore</surname><given-names>AT</given-names></name></person-group><year>2010</year><article-title>Novel mutations in MERTK associated with childhood onset rod-cone dystrophy</article-title><source>Molecular Vision</source><volume>16</volume><fpage>369</fpage><lpage>377</lpage></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mark</surname><given-names>MR</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hammonds</surname><given-names>RG</given-names></name><name><surname>Sadick</surname><given-names>M</given-names></name><name><surname>Godowsk</surname><given-names>PJ</given-names></name></person-group><year>1996</year><article-title>Characterization of Gas6, a member of the superfamily of G domain-containing proteins, as a ligand for Rse and Axl</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>9785</fpage><lpage>9789</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.16.9785</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McColl</surname><given-names>A</given-names></name><name><surname>Bournazos</surname><given-names>S</given-names></name><name><surname>Franz</surname><given-names>S</given-names></name><name><surname>Perretti</surname><given-names>M</given-names></name><name><surname>Morgan</surname><given-names>BP</given-names></name><name><surname>Haslett</surname><given-names>C</given-names></name><name><surname>Dransfield</surname><given-names>I</given-names></name></person-group><year>2009</year><article-title>Glucocorticoids induce protein S-dependent phagocytosis of apoptotic neutrophils by human macrophages</article-title><source>The Journal of Immunology</source><volume>183</volume><fpage>2167</fpage><lpage>2175</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0803503</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meertens</surname><given-names>L</given-names></name><name><surname>Carnec</surname><given-names>X</given-names></name><name><surname>Perera Lecoin</surname><given-names>M</given-names></name><name><surname>Ramdasi</surname><given-names>R</given-names></name><name><surname>Guivel-Benhassine</surname><given-names>F</given-names></name><name><surname>Lew</surname><given-names>E</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Schwartz</surname><given-names>O</given-names></name><name><surname>Amara</surname><given-names>A</given-names></name></person-group><year>2012</year><article-title>TIM and TAM receptors mediate dengue virus infection</article-title><source>Cell Host &amp; Microbe</source><volume>12</volume><fpage>544</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2012.08.009</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meyer</surname><given-names>AS</given-names></name><name><surname>Miller</surname><given-names>MA</given-names></name><name><surname>Gertler</surname><given-names>FB</given-names></name><name><surname>Lauffenburger</surname><given-names>DA</given-names></name></person-group><year>2013</year><article-title>The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells</article-title><source>Science Signaling</source><volume>6</volume><fpage>ra66</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2004155</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morizono</surname><given-names>K</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Olafsen</surname><given-names>T</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Dasgupta</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>AM</given-names></name><name><surname>Chen</surname><given-names>IS</given-names></name></person-group><year>2011</year><article-title>The soluble serum protein Gas6 bridges virion envelope phosphatidylserine to the TAM receptor tyrosine kinase Axl to mediate viral entry</article-title><source>Cell Host &amp; Microbe</source><volume>9</volume><fpage>286</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2011.03.012</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Arita</surname><given-names>H</given-names></name><name><surname>Zong</surname><given-names>C</given-names></name><name><surname>Hanafusa</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name></person-group><year>1996</year><article-title>Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases</article-title><source>The Journal of Biological Chemistry</source><volume>271</volume><fpage>30022</fpage><lpage>30027</lpage><pub-id pub-id-type="doi">10.1074/jbc.271.47.30022</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nagata</surname><given-names>S</given-names></name><name><surname>Hanayama</surname><given-names>R</given-names></name><name><surname>Kawane</surname><given-names>K</given-names></name></person-group><year>2010</year><article-title>Autoimmunity and the clearance of dead cells</article-title><source>Cell</source><volume>140</volume><fpage>619</fpage><lpage>630</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.014</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Kawamoto</surname><given-names>K</given-names></name><name><surname>Kishino</surname><given-names>J</given-names></name><name><surname>Nomura</surname><given-names>K</given-names></name><name><surname>Higashino</surname><given-names>K</given-names></name><name><surname>Arita</surname><given-names>H</given-names></name></person-group><year>1997</year><article-title>Requirement of gamma-carboxyglutamic acid residues for the biological activity of Gas6: contribution of endogenous Gas6 to the proliferation of vascular smooth muscle cells</article-title><source>The Biochemical Journal</source><volume>323</volume><fpage>387</fpage><lpage>392</lpage></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandrot</surname><given-names>EF</given-names></name><name><surname>Dufour</surname><given-names>EM</given-names></name></person-group><year>2010</year><article-title>Mertk in daily retinal phagocytosis: a history in the making</article-title><source>Advances in Experimental Medicine and Biology</source><volume>664</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-1399-9_16</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nelsestuen</surname><given-names>GL</given-names></name><name><surname>Shah</surname><given-names>AM</given-names></name><name><surname>Harvey</surname><given-names>SB</given-names></name></person-group><year>2000</year><article-title>Vitamin K-dependent proteins</article-title><source>Vitamins and Hormones</source><volume>58</volume><fpage>355</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/S0083-6729(00)58031-5</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Bryan</surname><given-names>JP</given-names></name><name><surname>Fridell</surname><given-names>YW</given-names></name><name><surname>Koski</surname><given-names>R</given-names></name><name><surname>Varnum</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name></person-group><year>1995</year><article-title>The transforming receptor tyrosine kinase, Axl, is post-translationally regulated by proteolytic cleavage</article-title><source>The Journal of Biological Chemistry</source><volume>270</volume><fpage>551</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.2.551</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><name><surname>Toshima</surname><given-names>J</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Arita</surname><given-names>H</given-names></name><name><surname>Tsuda</surname><given-names>H</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name></person-group><year>1995</year><article-title>Stimulation of sky receptor tyrosine kinase by the product of growth arrest-specific gene 6</article-title><source>The Journal of Biological Chemistry</source><volume>270</volume><fpage>22681</fpage><lpage>22684</lpage><pub-id pub-id-type="doi">10.1074/jbc.270.39.22681</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ostergaard</surname><given-names>E</given-names></name><name><surname>Duno</surname><given-names>M</given-names></name><name><surname>Batbayli</surname><given-names>M</given-names></name><name><surname>Vilhelmsen</surname><given-names>K</given-names></name><name><surname>Rosenberg</surname><given-names>T</given-names></name></person-group><year>2011</year><article-title>A novel MERTK deletion is a common founder mutation in the Faroe Islands and is responsible for a high proportion of retinitis pigmentosa cases</article-title><source>Molecular Vision</source><volume>17</volume><fpage>1485</fpage><lpage>1492</lpage></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paccez</surname><given-names>JD</given-names></name><name><surname>Vogelsang</surname><given-names>M</given-names></name><name><surname>Parker</surname><given-names>MI</given-names></name><name><surname>Zerbini</surname><given-names>LF</given-names></name></person-group><year>2014</year><article-title>The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications</article-title><source>International Journal of Cancer</source><volume>134</volume><fpage>1024</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1002/ijc.28246</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>D</given-names></name><name><surname>Rothlin</surname><given-names>CV</given-names></name><name><surname>Burrola</surname><given-names>P</given-names></name><name><surname>Burstyn-Cohen</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Garcia de Frutos</surname><given-names>P</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2006</year><article-title>TAM receptor function in the retinal pigment epithelium</article-title><source>Molecular and Cellular Neurosciences</source><volume>33</volume><fpage>96</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1016/j.mcn.2006.06.011</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajotte</surname><given-names>I</given-names></name><name><surname>Hasanbasic</surname><given-names>I</given-names></name><name><surname>Blostein</surname><given-names>M</given-names></name></person-group><year>2008</year><article-title>Gas6-mediated signaling is dependent on the engagement of its gamma-carboxyglutamic acid domain with phosphatidylserine</article-title><source>Biochemical and Biophysical Research Communications</source><volume>376</volume><fpage>70</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2008.08.083</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothlin</surname><given-names>CV</given-names></name><name><surname>Ghosh</surname><given-names>S</given-names></name><name><surname>Zuniga</surname><given-names>EI</given-names></name><name><surname>Oldstone</surname><given-names>MB</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2007</year><article-title>TAM receptors are pleiotropic inhibitors of the innate immune response</article-title><source>Cell</source><volume>131</volume><fpage>1124</fpage><lpage>1136</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.10.034</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothlin</surname><given-names>CV</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2010</year><article-title>TAM receptor signaling and autoimmune disease</article-title><source>Current Opinion in Immunology</source><volume>22</volume><fpage>740</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2010.10.001</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruggiero</surname><given-names>L</given-names></name><name><surname>Connor</surname><given-names>MP</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Langen</surname><given-names>R</given-names></name><name><surname>Finnemann</surname><given-names>SC</given-names></name></person-group><year>2012</year><article-title>Diurnal, localized exposure of phosphatidylserine by rod outer segment tips in wild-type but not Itgb5-/- or Mfge8-/- mouse retina</article-title><source>Proceedings of the National Academy of Sciences of USA</source><volume>109</volume><fpage>8145</fpage><lpage>8148</lpage><pub-id pub-id-type="doi">10.1073/pnas.1121101109</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Knyazev</surname><given-names>PG</given-names></name><name><surname>Cheburkin</surname><given-names>Y</given-names></name><name><surname>Gohring</surname><given-names>W</given-names></name><name><surname>Tisi</surname><given-names>D</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Timpl</surname><given-names>R</given-names></name><name><surname>Hohenester</surname><given-names>E</given-names></name></person-group><year>2002</year><article-title>Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6. Receptor tyrosine kinase activation by laminin G-like domains</article-title><source>The Journal of Biological Chemistry</source><volume>277</volume><fpage>44164</fpage><lpage>44170</lpage><pub-id pub-id-type="doi">10.1074/jbc.M207340200</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Knyazev</surname><given-names>PG</given-names></name><name><surname>Clout</surname><given-names>NJ</given-names></name><name><surname>Cheburkin</surname><given-names>Y</given-names></name><name><surname>Gohring</surname><given-names>W</given-names></name><name><surname>Ullrich</surname><given-names>A</given-names></name><name><surname>Timpl</surname><given-names>R</given-names></name><name><surname>Hohenester</surname><given-names>E</given-names></name></person-group><year>2006</year><article-title>Structural basis for Gas6-Axl signalling</article-title><source>The EMBO Journal</source><volume>25</volume><fpage>80</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600912</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sather</surname><given-names>S</given-names></name><name><surname>Kenyon</surname><given-names>KD</given-names></name><name><surname>Lefkowitz</surname><given-names>JB</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Varnum</surname><given-names>BC</given-names></name><name><surname>Henson</surname><given-names>PM</given-names></name><name><surname>Graham</surname><given-names>DK</given-names></name></person-group><year>2007</year><article-title>A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation</article-title><source>Blood</source><volume>109</volume><fpage>1026</fpage><lpage>1033</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-05-021634</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlegel</surname><given-names>J</given-names></name><name><surname>Sambade</surname><given-names>MJ</given-names></name><name><surname>Sather</surname><given-names>S</given-names></name><name><surname>Moschos</surname><given-names>SJ</given-names></name><name><surname>Tan</surname><given-names>AC</given-names></name><name><surname>Winges</surname><given-names>A</given-names></name><name><surname>DeRyckere</surname><given-names>D</given-names></name><name><surname>Carson</surname><given-names>CC</given-names></name><name><surname>Trembath</surname><given-names>DG</given-names></name><name><surname>Tentler</surname><given-names>JJ</given-names></name><name><surname>Eckhardt</surname><given-names>SG</given-names></name><name><surname>Kuan</surname><given-names>PF</given-names></name><name><surname>Hamilton</surname><given-names>RL</given-names></name><name><surname>Duncan</surname><given-names>LM</given-names></name><name><surname>Miller</surname><given-names>CR</given-names></name><name><surname>Nikolaishvili-Feinberg</surname><given-names>N</given-names></name><name><surname>Midkiff</surname><given-names>BR</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Frye</surname><given-names>SV</given-names></name><name><surname>Earp</surname><given-names>HS</given-names></name><name><surname>Shields</surname><given-names>JM</given-names></name><name><surname>Graham</surname><given-names>DK</given-names></name></person-group><year>2013</year><article-title>MERTK receptor tyrosine kinase is a therapeutic target in melanoma</article-title><source>The Journal of Clinical Investigation</source><volume>123</volume><fpage>2257</fpage><lpage>2267</lpage><pub-id pub-id-type="doi">10.1172/JCI67816</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scott</surname><given-names>RS</given-names></name><name><surname>McMahon</surname><given-names>EJ</given-names></name><name><surname>Pop</surname><given-names>SM</given-names></name><name><surname>Reap</surname><given-names>EA</given-names></name><name><surname>Caricchio</surname><given-names>R</given-names></name><name><surname>Cohen</surname><given-names>PL</given-names></name><name><surname>Earp</surname><given-names>HS</given-names></name><name><surname>Matsushima</surname><given-names>GK</given-names></name></person-group><year>2001</year><article-title>Phagocytosis and clearance of apoptotic cells is mediated by MER</article-title><source>Nature</source><volume>411</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1038/35075603</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seitz</surname><given-names>HM</given-names></name><name><surname>Camenisch</surname><given-names>TD</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Earp</surname><given-names>HS</given-names></name><name><surname>Matsushima</surname><given-names>GK</given-names></name></person-group><year>2007</year><article-title>Macrophages and dendritic cells use different Axl/Mertk/Tyro3 receptors in clearance of apoptotic cells</article-title><source>The Journal of Immunology</source><volume>178</volume><fpage>5635</fpage><lpage>5642</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.178.9.5635</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shibata</surname><given-names>T</given-names></name><name><surname>Habiel</surname><given-names>DM</given-names></name><name><surname>Coelho</surname><given-names>AL</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Lukacs</surname><given-names>NW</given-names></name><name><surname>Hogaboam</surname><given-names>CM</given-names></name></person-group><year>2014</year><article-title>Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma</article-title><source>The Journal of Immunology</source><volume>192</volume><fpage>3569</fpage><lpage>3581</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1302766</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shimojima</surname><given-names>M</given-names></name><name><surname>Takada</surname><given-names>A</given-names></name><name><surname>Ebihara</surname><given-names>H</given-names></name><name><surname>Neumann</surname><given-names>G</given-names></name><name><surname>Fujioka</surname><given-names>K</given-names></name><name><surname>Irimura</surname><given-names>T</given-names></name><name><surname>Jones</surname><given-names>S</given-names></name><name><surname>Feldmann</surname><given-names>H</given-names></name><name><surname>Kawaoka</surname><given-names>Y</given-names></name></person-group><year>2006</year><article-title>Tyro3 family-mediated cell entry of Ebola and Marburg viruses</article-title><source>Journal of Virology</source><volume>80</volume><fpage>10109</fpage><lpage>10116</lpage><pub-id pub-id-type="doi">10.1128/JVI.01157-06</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiratsuchi</surname><given-names>A</given-names></name><name><surname>Umeda</surname><given-names>M</given-names></name><name><surname>Ohba</surname><given-names>Y</given-names></name><name><surname>Nakanishi</surname><given-names>Y</given-names></name></person-group><year>1997</year><article-title>Recognition of phosphatidylserine on the surface of apoptotic spermatogenic cells and subsequent phagocytosis by Sertoli cells of the rat</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>2354</fpage><lpage>2358</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.4.2354</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stafford</surname><given-names>DW</given-names></name></person-group><year>2005</year><article-title>The vitamin K cycle</article-title><source>Journal of Thrombosis and Haemostasis</source><volume>3</volume><fpage>1873</fpage><lpage>1878</lpage><pub-id pub-id-type="doi">10.1111/j.1538-7836.2005.01419.x</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stitt</surname><given-names>TN</given-names></name><name><surname>Conn</surname><given-names>G</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Lai</surname><given-names>C</given-names></name><name><surname>Bruno</surname><given-names>J</given-names></name><name><surname>Radziejewski</surname><given-names>C</given-names></name><name><surname>Mattsson</surname><given-names>K</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name><name><surname>Gies</surname><given-names>DR</given-names></name><name><surname>Jones</surname><given-names>PF</given-names></name><name><surname>Masiakowski</surname><given-names>P</given-names></name><name><surname>Ryan</surname><given-names>TE</given-names></name><name><surname>Tobkes</surname><given-names>NJ</given-names></name><name><surname>Chen</surname><given-names>DH</given-names></name><name><surname>DiStefano</surname><given-names>PS</given-names></name><name><surname>Long</surname><given-names>GL</given-names></name><name><surname>Basilico</surname><given-names>C</given-names></name><name><surname>Goldfarb</surname><given-names>M</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name><name><surname>Glass</surname><given-names>D</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name></person-group><year>1995</year><article-title>The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro 3/Axl family of receptor tyrosine kinases</article-title><source>Cell</source><volume>80</volume><fpage>661</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(95)90520-0</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Strauss</surname><given-names>O</given-names></name></person-group><year>2005</year><article-title>The retinal pigment epithelium in visual function</article-title><source>Physiological Reviews</source><volume>85</volume><fpage>845</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1152/physrev.00021.2004</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tanabe</surname><given-names>K</given-names></name><name><surname>Nagata</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>K</given-names></name><name><surname>Nakano</surname><given-names>T</given-names></name><name><surname>Arita</surname><given-names>H</given-names></name><name><surname>Mizuno</surname><given-names>K</given-names></name></person-group><year>1997</year><article-title>Roles of gamma-carboxylation and a sex hormone-binding globulin-like domain in receptor-binding and in biological activities of Gas6</article-title><source>FEBS Letters</source><volume>408</volume><fpage>306</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/S0014-5793(97)00448-1</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsou</surname><given-names>WI</given-names></name><name><surname>Nguyen</surname><given-names>KQ</given-names></name><name><surname>Calarese</surname><given-names>DA</given-names></name><name><surname>Garforth</surname><given-names>SJ</given-names></name><name><surname>Antes</surname><given-names>AL</given-names></name><name><surname>Smirnov</surname><given-names>SV</given-names></name><name><surname>Almo</surname><given-names>SC</given-names></name><name><surname>Birge</surname><given-names>RB</given-names></name><name><surname>Kotenko</surname><given-names>SV</given-names></name></person-group><year>2014</year><article-title>Receptor tyrosine kinases, TYRO3, AXL and MER, demonstrate distinct patterns and complex regulation of ligand-induced activation</article-title><source>The Journal of Biological Chemistry</source><volume>289</volume><fpage>25750</fpage><lpage>25763</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.569020</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uehara</surname><given-names>H</given-names></name><name><surname>Shacter</surname><given-names>E</given-names></name></person-group><year>2008</year><article-title>Auto-oxidation and oligomerization of protein S on the apoptotic cell surface is required for Mer tyrosine kinase-mediated phagocytosis of apoptotic cells</article-title><source>The Journal of Immunology</source><volume>180</volume><fpage>2522</fpage><lpage>2530</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.4.2522</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Brand</surname><given-names>BT</given-names></name><name><surname>Abdollahi-Roodsaz</surname><given-names>S</given-names></name><name><surname>Vermeij</surname><given-names>EA</given-names></name><name><surname>Bennink</surname><given-names>MB</given-names></name><name><surname>Arntz</surname><given-names>OJ</given-names></name><name><surname>Rothlin</surname><given-names>CV</given-names></name><name><surname>van den Berg</surname><given-names>WB</given-names></name><name><surname>van de Loo</surname><given-names>FA</given-names></name></person-group><year>2013</year><article-title>Therapeutic efficacy of Tyro3, Axl, and Mer tyrosine kinase agonists in collagen-induced arthritis</article-title><source>Arthritis and Rheumatism</source><volume>65</volume><fpage>671</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1002/art.37786</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Meer</surname><given-names>G</given-names></name><name><surname>Voelker</surname><given-names>DR</given-names></name><name><surname>Feigenson</surname><given-names>GW</given-names></name></person-group><year>2008</year><article-title>Membrane lipids: where they are and how they behave</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>9</volume><fpage>112</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1038/nrm2330</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varnum</surname><given-names>BC</given-names></name><name><surname>Young</surname><given-names>C</given-names></name><name><surname>Elliott</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>A</given-names></name><name><surname>Bartley</surname><given-names>TD</given-names></name><name><surname>Fridell</surname><given-names>YW</given-names></name><name><surname>Hunt</surname><given-names>RW</given-names></name><name><surname>Trail</surname><given-names>G</given-names></name><name><surname>Clogston</surname><given-names>C</given-names></name><name><surname>Toso</surname><given-names>RJ</given-names></name><name><surname>Yanagihara</surname><given-names>D</given-names></name><name><surname>Bennett</surname><given-names>L</given-names></name><name><surname>Sylber</surname><given-names>M</given-names></name><name><surname>Merewether</surname><given-names>LA</given-names></name><name><surname>Tseng</surname><given-names>A</given-names></name><name><surname>Escobar</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>ET</given-names></name><name><surname>Yamane</surname><given-names>HK</given-names></name></person-group><year>1995</year><article-title>Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6</article-title><source>Nature</source><volume>373</volume><fpage>623</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1038/373623a0</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>I</given-names></name><name><surname>Nagyoszi</surname><given-names>P</given-names></name><name><surname>Farkas</surname><given-names>AE</given-names></name><name><surname>Couraud</surname><given-names>PO</given-names></name><name><surname>Romero</surname><given-names>IA</given-names></name><name><surname>Weksler</surname><given-names>B</given-names></name><name><surname>Fazakas</surname><given-names>C</given-names></name><name><surname>Dung</surname><given-names>NT</given-names></name><name><surname>Bottka</surname><given-names>S</given-names></name><name><surname>Bauer</surname><given-names>H</given-names></name><name><surname>Bauer</surname><given-names>HC</given-names></name><name><surname>Krizbai</surname><given-names>IA</given-names></name></person-group><year>2008</year><article-title>Hyperosmotic stress induces Axl activation and cleavage in cerebral endothelial cells</article-title><source>Journal of Neurochemistry</source><volume>107</volume><fpage>116</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1111/j.1471-4159.2008.05590.x</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>J</given-names></name></person-group><year>2005</year><article-title>Preparation, culture, and immortalization of mouse embryonic fibroblasts</article-title><source>Current Protocols in Molecular Biology</source><comment>Chapter 28:Unit 28.1</comment><pub-id pub-id-type="doi">10.1002/0471142727.mb2801s70</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Stawicki</surname><given-names>S</given-names></name><name><surname>Couto</surname><given-names>S</given-names></name><name><surname>Eastham-Anderson</surname><given-names>J</given-names></name><name><surname>Kallop</surname><given-names>D</given-names></name><name><surname>Weimer</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Pei</surname><given-names>L</given-names></name></person-group><year>2010</year><article-title>An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies</article-title><source>Oncogene</source><volume>29</volume><fpage>5254</fpage><lpage>5264</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.268</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zagórska</surname><given-names>A</given-names></name><name><surname>Través</surname><given-names>PG</given-names></name><name><surname>Lew</surname><given-names>ED</given-names></name><name><surname>Dransfield</surname><given-names>I</given-names></name><name><surname>Lemke</surname><given-names>G</given-names></name></person-group><year>2014</year><article-title>Diversification of TAM receptor tyrosine kinase function</article-title><source>Nature Immunology</source><volume>15</volume><fpage>920</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1038/ni.2986</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Lee</surname><given-names>JC</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Olivas</surname><given-names>V</given-names></name><name><surname>Au</surname><given-names>V</given-names></name><name><surname>LaFramboise</surname><given-names>T</given-names></name><name><surname>Abdel-Rahman</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Levine</surname><given-names>AD</given-names></name><name><surname>Rho</surname><given-names>JK</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Choi</surname><given-names>CM</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Jang</surname><given-names>SJ</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Kim</surname><given-names>WS</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Arcila</surname><given-names>M</given-names></name><name><surname>Ladanyi</surname><given-names>M</given-names></name><name><surname>Moonsamy</surname><given-names>P</given-names></name><name><surname>Sawyers</surname><given-names>C</given-names></name><name><surname>Boggon</surname><given-names>TJ</given-names></name><name><surname>Ma</surname><given-names>PC</given-names></name><name><surname>Costa</surname><given-names>C</given-names></name><name><surname>Taron</surname><given-names>M</given-names></name><name><surname>Rosell</surname><given-names>R</given-names></name><name><surname>Halmos</surname><given-names>B</given-names></name><name><surname>Bivona</surname><given-names>TG</given-names></name></person-group><year>2012</year><article-title>Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</article-title><source>Nature Genetics</source><volume>44</volume><fpage>852</fpage><lpage>860</lpage><pub-id pub-id-type="doi">10.1038/ng.2330</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>H</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name></person-group><year>2014</year><article-title>Different expression patterns and clinical significance of mAxl and sAxl in systemic lupus erythematosus</article-title><source>Lupus</source><volume>23</volume><fpage>624</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1177/0961203314520839</pub-id></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.03385.017</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Goff</surname><given-names>Stephen P</given-names></name><role>Reviewing editor</role><aff><institution>Howard Hughes Medical Institute, Columbia University</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see <ext-link ext-link-type="uri" xlink:href="http://elifesciences.org/review-process">review process</ext-link>). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.</p></boxed-text><p>Thank you for sending your work entitled “Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities” for consideration at <italic>eLife</italic>. Your article has been favorably evaluated by Charles Sawyers (Senior editor), a Reviewing editor, and 3 reviewers.</p><p>The Reviewing editor has assembled the following comments to help you prepare a revised submission.</p><p>A common complaint is the use of human S protein in much of the work instead of the murine S protein. This seems to be a big problem in the reviewers' minds and will need to be addressed. Either much of the work will have to be repeated with the mouse protein, or some disclaimers will have to be injected into the paper that convince us that this is not an important issue.</p><p>There are several complaints about quantification of the responses, titration of stimuli, error bars, and saturation of responses. The points seem clearly laid out. I think the complaints have merit and need to be addressed, either experimentally or verbally. Good quantification, with error bars, is needed to validate the claims drawn from the data. This would seem to be a major part of the paper and so must be dealt with.</p><p><italic>Reviewer 1 major comments</italic>:</p><p>The paper describes a large body of work to address important questions related to the TAM receptors and their ligands. The authors have created unique reagents and the results obtained are very interesting and valid. The paper addresses questions that have previously been studied by others, but the unique set of reagents make it possible for them to give clear answers. The work is of high quality and the conclusions are valid. I have the following concerns the authors need to address:</p><p>The authors have used human protein S in the majority of the experiments as it showed to be more potent than murine protein S as a TAM-activator. In a study wanting to compare the physiological role of TAMs and their ligands in a defined setting, this is not really relevant. The study would benefit from using murine protein S throughout the study.</p><p>In the experiments testing the thrombin-cleavage-dependent effects of protein S, I am not convinced the protein S has been fully processed. Have the authors verified that the thrombin cleavage is complete (e.g. using a GLA-antibody on a western blot)? As the authors state that only half the physiological amounts of protein S is needed in vivo to activate TAMs, a partial thrombin cleavage might not show strong effects in a stimulation experiment. Likewise, it would be good to use in addition a lower protein S concentration for the stimulation to see a dose dependence, as well as to study also Mer phosphorylation in the same setup. In addition, it is not clear to me why the authors have used mouse proteinS for this experiment whereas most other are performed with human protein S.</p><p>The authors discuss the role of ptdser in TAM activation by Gas6 and suggest that ptdser is always needed for optimal TAM activation. An experiment on receptor phosphorylation in the presence of an excess of liposomes with and without ptdser could easily show if there is an added effect of circulating ptdser. In addition, it is not clear whether the authors suggest that ptdser-exposure on the same cell as TAM-expression or ptdser in circulation/on interacting cells is the crucial factor.</p><p>The authors claim that sAxl is released from the cell surface upon Axl activation. This has not been clearly shown and should not be addressed as a fact. An experiment studying sAxl release into the cell culture supernatant upon Gas6-mediated Axl stimulation could give more support to this claim.</p><p><italic>Reviewer 2 major comments</italic>:</p><p>Lew et al. describe an interesting set of studies of ligand engagement and activation in the TAM family, clearing up several important issues and providing some valuable observations. Using purified ligands and MEFs engineered to express single TAMs (a clear and elegant system for these studies), they show that Gas6 functions as a ligand for Tyro3, Axl, and Mer. They argue that Axl is most potently activated (see point1 and 2 below). On the other hand, the authors show that Pros1 activates Tyro3 and Mer, but argue that it does not activate Axl ( see point 1 and 3 below). They further show that the Gla domain is important for activation – but not necessarily for receptor binding, and Axl appears most dependent on the presence of the Gla domain in Gas6 (see point 4 below). The observed differences appear to track with the Ig domains of the receptors. Finally, the data supporting Pros1/Mer signaling in retinal phagocytosis are quite compelling, and isolate that signaling axis impressively in an <italic>in vivo</italic> setting, and seem to support separate signaling functions of each receptor/ligand pair.</p><p>The systems used to tease out the signaling relationships here are excellent, and the data very informative for a poorly understood and interesting system. As a result, the manuscript should be of wide interest. There are a few important problems, though, most notably the tendency to draw quantitative conclusions about relative potencies from dose-response curves that are not saturated, and from data presented without proper quantitation or assessment of error (see point 1). The conclusions seem like they are broadly correct, but these biochemical data need to be presented in a way that can be objectively evaluated. Points 1-3 focus on this issue, which really needs to be addressed properly before publication should be considered.</p><p>Major points:</p><p>1) There is a general concern throughout the manuscript that interpretations about relative potencies (and half-max ligand concentrations) are made without quantitation or (therefore) error bars – and it is not stated how many repeats of each analysis were done. This issue resurfaces in several of the comments below that concern quantitative interpretations. Using Licor to follow tyrosine phosphorylation, results of quantification of 3 or more repeats needs to be shown, with error, for comparison of potencies etc.</p><p>2) The dose-response assessment in <xref ref-type="fig" rid="fig2">Figure 2B</xref> does not really show that rmGas6 is a 'more effective' ligand for Axl than Tyro3. Neither assessment reaches saturation of receptor phosphorylation (see point 1 above), and the trends with ligand concentration look very similar as far as they go. If the two receptors saturate at different pY/4G10 signals, the half maximal values may very well be the same (with no higher activation for Axl). There are similar problems with many of the dose-response curves in the paper (although signal may be saturated in rmGas6 activation of Tyro3 in <xref ref-type="fig" rid="fig2">Figure 2D</xref>, and in <xref ref-type="fig" rid="fig3 fig5">Figure 3A and 5</xref>), making comparisons difficult.</p><p>3) Given the background signal in <xref ref-type="fig" rid="fig2">Figure 2C</xref> (compared with 2E), it is difficult to be completely convinced that hPros1 activates Mer but not Axl. There is clearly some Mer activation - although it remains unclear what hPros1 concentration is required to saturate. For Axl in <xref ref-type="fig" rid="fig2">Figure 2C</xref>, comparison of the 5, 10, and 50nM lanes suggest some activation - but the 100nM lane argues otherwise (how many times was this done - the authors do not say). It is difficult to know whether this is a problem with just that sample. Comparing Pros1 activation of Mer in <xref ref-type="fig" rid="fig2">Figure 2F and</xref> (claimed lack of) Axl activation in <xref ref-type="fig" rid="fig2">Figure 2C</xref> also reduces confidence. The data need to be quantitated in order to make the quantitative comparison made here (as done for Mer in <xref ref-type="fig" rid="fig2">Figure 2F</xref> but not for Axl in <xref ref-type="fig" rid="fig2">Figure 2C</xref>). Error bars also need to be provided for the Licor-based quantitation – with statement of how many repeats were performed – if the case for Pros1 activation of Mer but not Axl is to be made convincingly.</p><p>4) One has to wonder how physiologically significant is the difference between Axl and the other TAMs in terms of Gla domain dependence. Whereas Gla-less Gas6 seems to lose efficacy for Axl, removal of the Gla domain still reduces potency perhaps 20-50 fold for Mer and Tyro3. It would be helpful for the authors to put this into physiological context. What is the functional difference between 'dead' and 20-50 fold impaired for Gas6? Is there any?</p><p>5) Was cell surface expression of ECDTIgITKA confirmed, to exclude the trivial possibility that it is not accessible to hPros1 in <xref ref-type="fig" rid="fig5">Figure 5D</xref>?</p><p><italic>Reviewer 3 major comments</italic>:</p><p>Lew et.al. investigated the mechanisms of signaling mediated by Gas6 and protein S via interaction(s) with TAM receptors (TYRO3, Axl, Mer). Cell lines derived from TAM knockout mice enabled them to analyze the ability of Gas6 and protein S to elicit signaling from each type of TAM receptor by ectopically expressing one type of the receptors. They found that Gas6 can elicit signaling through all TAM receptors, while protein S can only do so through Mer and TYRO3. Using chimeric receptors, they demonstrated that the extracellular Ig domains of the receptors determine the ability of the receptors to elicit signaling in response to protein S. They also found that interactions between the Gla domain of protein S/Gas6 and phosphatidylserine are necessary for optimal signaling. They analyzed the roles of protein S, Gas6, and TAM receptors in phagocytosis in the retina and testis, using various types of knockout mice. Based upon analysis of knockout mouse phenotypes and their data from <italic>in vitro</italic> analysis of the signaling mechanisms, they claim that Mer and protein S play a predominant role in phagocytosis in the retina and testis. This reviewer sees two major concerns regarding experimental design used in this study:</p><p>1) The authors used human protein S in studies investigating the mechanisms of signaling in murine TAM receptors (<xref ref-type="fig" rid="fig2 fig5 fig6">Figures 2C F, 5D, and 6B</xref>). Because the activity and specificity of protein S and Gas6 could be species-specific (ref. Hafizi and Darlback, FEBS J., 2006), it is not clear whether all the data acquired with human protein S are applicable to the signaling mechanisms of murine protein S. In addition, preparation of human protein S differed from that of murine protein S and Gas6; human protein S was purified from human serum, and both murine and human protein S were generated as His-tag-conjugated recombinant proteins. Therefore, comparison of human protein S and murine Gas6 abilities to induce signaling can be influenced by many factors, including purification methods, presence of tag sequence, and efficiency and types of post-translational modifications.</p><p>Because the data that compare signaling activity and specificity of murine protein S and Gas6 are very important to properly interpret the mouse <italic>in vivo</italic> data, most of the <italic>in vitro</italic> experiments investigating signaling mechanisms of protein S should be performed using murine protein S.</p><p>2) The authors claim that PtdSer exposed on a small fraction of cultured cells binds to the Gla domain of protein S and Gas6, and this binding is necessary for optimal signaling via TAM receptors. To clearly show that PtdSer exposed on minor cell populations plays a critical role in Gas6/protein S signaling, it will be necessary to demonstrate that induction of PtdSer exposure and elimination of exposed PtdSer on cells affect the magnitude of signaling by protein S/Gas6.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.03385.018</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>A common complaint is the use of human S protein in much of the work instead of the murine S protein. This seems to be a big problem in the reviewers' minds and will need to be addressed. Either much of the work will have to be repeated with the mouse protein, or some disclaimers will have to be injected into the paper that convince us that this is not an important issue</italic>.</p><p>As detailed below, we have done both. We have included significant additional data using recombinant mouse Protein S as a ligand for the TAMs, and have also cited recently published (e-published ahead of print) work in which human and mouse Protein S were found to be equivalent with respect to their ability to activate a hybrid receptor composed of either the Tyro3 or Mer extracellular domain linked to the cytoplasmic domain of the R1 chain of the IFNγ receptor. (Activation of the hybrid chimeras was monitored by STAT1 phosphorylation.) In general, we have used the purified human protein only because it is (for unknown reasons) more stable biochemically over time than the recombinant mouse protein that we produce and purify. However, we now show that both purified human and recombinant mouse Protein S have the same receptor specificity.</p><p><italic>There are several complaints about quantification of the responses, titration of stimuli, error bars, and saturation of responses. The points seem clearly laid out. I think the complaints have merit and need to be addressed, either experimentally or verbally. Good quantification, with error bars, is needed to validate the claims drawn from the data. This would seem to be a major part of the paper and so must be dealt with</italic>.</p><p>We have addressed issues with respect to quantitation and reproducibility, which primarily relate to <xref ref-type="fig" rid="fig2">Figure 2</xref>, as outlined below in our responses to the individual reviews.</p><p>Reviewer 1 major comments:</p><p><italic>[…] The work is of high quality and the conclusions are valid. I have the following concerns the authors need to address</italic>:</p><p><italic>The authors have used human protein S in the majority of the experiments as it showed to be more potent than murine protein S as a TAM-activator. In a study wanting to compare the physiological role of TAMs and their ligands in a defined setting, this is not really relevant. The study would benefit from using murine protein S throughout the study</italic>.</p><p>The human Protein S we have used is a commercial product (Enzyme Research Laboratories) purified from human plasma, whereas the mouse Protein S is a recombinant protein that we have expressed and purified in-house. For unknown reasons, the purified human protein is in our hands slightly more potent and significantly more stable biochemically than the recombinant mouse protein.</p><p>This is the main reason that we have used it for many of our experiments. However, both the human and mouse proteins show the same specificity and are active ligands for mouse Tyro3 and Mer. We have now indicated this in the Results section of the revised paper. As suggested by Reviewer 1, we have also included additional results obtained with our recombinant mouse Protein S, in <xref ref-type="fig" rid="fig2">Figure 2</xref>, panels B, E and <xref ref-type="fig" rid="fig2s1">Figure 2-figure supplement 1</xref>. We have also cited a recent paper from Tsou <italic>et al.</italic> (<italic>J. Biol. Chem</italic>., in press, pii: jbc.M114.569020) in which mouse Protein S and human Protein S were compared with respect to their ability to induce STAT1 phosphorylation upon activation of a hybrid receptor composed of either the Tyro3 or Mer extracellular domain linked to the cytoplasmic domain of the R1 chain of the interferon-γ receptor. Human and mouse Protein S were found to be equivalently good ligands for both mouse Mer/γR1 and mouse Tyro3/γR1, as monitored by the activation of STAT1.</p><p><italic>In the experiments testing the thrombin-cleavage-dependent effects of protein S, I am not convinced the protein S has been fully processed. Have the authors verified that the thrombin cleavage is complete (e.g. using a GLA-antibody on a western blot)? As the authors state that only half the physiological amounts of protein S is needed in vivo to activate TAMs, a partial thrombin cleavage might not show strong effects in a stimulation experiment. Likewise, it would be good to use in addition a lower protein S concentration for the stimulation to see a dose dependence, as well as to study also Mer phosphorylation in the same setup. In addition, it is not clear to me why the authors have used mouse proteinS for this experiment whereas most other are performed with human protein S</italic>.</p><p>Reviewer 1 is correct on each of these points. The problem that we face is that if we allow the thrombin incubation to run long enough for all of the Protein S to be cleaved, all of its bioactivity is lost. This is in spite of the fact that in intact serum, in which almost of the Protein S is thrombin-cleaved, the resident Protein S is a strong Tyro3 ligand. (It is important to remember that the objective of the experiment was test if cleavage is required to <italic>activate</italic> Protein S, which is apparently not the case since rmPros1 is active <italic>before</italic> thrombin cleavage.) Since these results are equivocal and not relevant to the main points of the paper, we have removed this supplemental panel from the revised paper.</p><p><italic>The authors discuss the role of ptdser in TAM activation by Gas6 and suggest that ptdser is always needed for optimal TAM activation. An experiment on receptor phosphorylation in the presence of an excess of liposomes with and without ptdser could easily show if there is an added effect of circulating ptdser</italic>.</p><p>We published a similar experiment last year (Bhattacharyya <italic>et al.</italic>, <italic>Cell Host &amp; Microbe</italic> 14(2): 136-47, <xref ref-type="fig" rid="fig3">Figure 3</xref>) in which we titered increasing concentrations of Gas6 and Protein S, in the absence or presence HIV-1-derived retroviruses that display PtdSer on the surface of their membrane envelopes. (The high level of surface PtdSer on HIV-1 allows the virus to be purified using Annexin V affinity methods; e.g., Callahan <italic>et al.</italic>, <italic>J. Immunol</italic>. 170: 4840.) We showed that the presence of the PtdSer-containing membranes dramatically shifted the dose-response curves (to lower protein concentration) for both Mer activation by Protein S and Axl activation by Gas6. In addition, the paper referenced as ‘Zagórska <italic>et al.</italic> submitted’ is now in press at <italic>Nature Immunology</italic>.</p><p>This paper contains a similar experiment using PtdSer-expressing apoptotic cells, and reaches the same conclusion. We have cited these experiments, and highlighted their significance in the Results section of the revised paper.</p><p><italic>In addition, it is not clear whether the authors suggest that ptdser-exposure on the same cell as TAM-expression or ptdser in circulation/on interacting cells is the crucial factor</italic>.</p><p>In the case of the two settings that we analyze genetically in the paper – the phagocytosis of the distal ends of photoreceptor outer segments by RPE cells in the eye, and the phagocytosis of apoptotic germ cells by Sertoli cells in the testis – the PtdSer is unambiguously expressed on the membrane surface of an apposed cell. Without question, this is also the case for the phagocytosis of apoptotic cells by macrophages. In all of these settings, the phagocyte has the TAM receptor, which is TAM-ligand-bridged to the engulfment target, which displays the PtdSer. We do not exclude the possibility the PtdSer-rich membranes might bind ligand and thereby activate a TAM receptor in the same cell, but we envision that the geometry of this signaling interaction will make these situations unusual.</p><p><italic>The authors claim that sAxl is released from the cell surface upon Axl activation. This has not been clearly shown and should not be addressed as a fact. An experiment studying sAxl release into the cell culture supernatant upon Gas6-mediated Axl stimulation could give more support to this claim</italic>.</p><p>Related experiments have been published. The Wilhelm <italic>et al.</italic> paper that we cite (<italic>J. Neurochem.</italic>, 2008, 107: 116) demonstrates that Axl cleavage by matrix metalloproteinases occurs subsequent to Axl activation (tyrosine phosphorylation), and can be inhibited by the broad-spectrum MMP inhibitor GM6001. We also cite (in the Discussion section of the revised paper) results from our in-press <italic>Nature Immunology</italic> paper, in which we show that antibody-induced Axl activation in tissues <italic>in vivo</italic> is accompanied by Axl proteolytic cleavage, and that the extent of cleavage is correlated with the level of Axl activation (more tyrosine phosphorylation, more cleavage).</p><p>Reviewer 2 major comments:</p><p><italic>[The] manuscript should be of wide interest. There are a few important problems, though, most notably the tendency to draw quantitative conclusions about relative potencies from dose-response curves that are not saturated, and from data presented without proper quantitation or assessment of error (see point 1). The conclusions seem like they are broadly correct, but these biochemical data need to be presented in a way that can be objectively evaluated. Points 1-3 focus on this issue, which really needs to be addressed properly before publication should be considered</italic>.</p><p><italic>Major points</italic>:</p><p><italic>1) There is a general concern throughout the manuscript that interpretations about relative potencies (and half-max ligand concentrations) are made without quantitation or (therefore) error bars – and it is not stated how many repeats of each analysis were done. This issue resurfaces in several of the comments below that concern quantitative interpretations. Using Licor to follow tyrosine phosphorylation, results of quantification of 3 or more repeats needs to be shown, with error, for comparison of potencies etc</italic>.</p><p>We have addressed these concerns with respect to activation profiles as detailed in our responses to the specific points of Reviewer 2 that follow. Although most of the immunoblots in the paper are indeed Licor blots, the panels showing Mer activation have a signal that is too low to be detected using Licor and these had to be developed using ECL (<xref ref-type="fig" rid="fig2">Figure 2</xref>, panels G, H, and supplement 1, as indicated in the figure legends). This is due to the lower Mer expression that we discuss in the Results section. Therefore, we could not use universal quantification for all the receptors. Instead we have shown multiple representative examples of our results. For example, in the revised <xref ref-type="fig" rid="fig2">Figure 2</xref>, the reader can now see three separate dose-response results for rmGas6 activation of Tyro3, all of which reach saturation. In the revised paper, we have also moderated the discussion of half-max ligand concentrations.</p><p><italic>2) The dose-response assessment in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2B</italic></xref> <italic>does not really show that rmGas6 is a 'more effective' ligand for Axl than Tyro3. Neither assessment reaches saturation of receptor phosphorylation (see point 1 above), and the trends with ligand concentration look very similar as far as they go. If the two receptors saturate at different pY/4G10 signals, the half maximal values may very well be the same (with no higher activation for Axl). There are similar problems with many of the dose-response curves in the paper (although signal may be saturated in rmGas6 activation of Tyro3 in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2D</italic></xref><italic>, and in</italic> <xref ref-type="fig" rid="fig3 fig5"><italic>Figure 3A and 5</italic></xref><italic>), making comparisons difficult</italic>.</p><p>Reviewer 2 has a valid point here. We chose MEF lines that express approximately equal levels of Tyro3 and Axl (based on expression of the HA tag) and we can often detect Axl phosphorylation at slightly lower Gas6 levels than we can detect Tyro3 activation. However, Gas6 is indeed a strong ligand for both Axl and Tyro3. (Compare, for example, new panels 2B first 8 lanes, 2D left 7 versus right 7 lanes, and 2E left 7 lanes. All of these new panels reach saturation.) We have revised the text accordingly, in the Results section. Perhaps the most salient point of the <xref ref-type="fig" rid="fig2">Figure 2</xref> analysis is that Axl can <italic>only</italic> be activated by Gas6.</p><p><italic>3) Given the background signal in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2C</italic></xref> <italic>(compared with 2E), it is difficult to be completely convinced that hPros1 activates Mer but not Axl. There is clearly some Mer activation - although it remains unclear what hPros1 concentration is required to saturate. For Axl in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2C</italic></xref><italic>, comparison of the 5, 10, and 50nM lanes suggest some activation - but the 100nM lane argues otherwise (how many times was this done - the authors do not say). It is difficult to know whether this is a problem with just that sample. Comparing Pros1 activation of Mer in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2F and</italic></xref> <italic>(claimed lack of) Axl activation in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2C</italic></xref> <italic>also reduces confidence. The data need to be quantitated in order to make the quantitative comparison made here (as done for Mer in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2F</italic></xref> <italic>but not for Axl in</italic> <xref ref-type="fig" rid="fig2"><italic>Figure 2C</italic></xref><italic>). Error bars also need to be provided for the Licor-based quantitation</italic> – <italic>with statement of how many repeats were performed</italic> – <italic>if the case for Pros1 activation of Mer but not Axl is to be made convincingly</italic>.</p><p>As indicated above in our response to Reviewer 1, we have added new additional data – in <xref ref-type="fig" rid="fig2">Figure 2</xref>, panels B and E and <xref ref-type="fig" rid="fig2s1">Figure 2–figure supplement 1</xref> – for titration of recombinant mouse Pros1 against both Axl and Tyro3 expressed in isolation in MEFs, and Mer expressed in Dex-treated macrophages. We have also added new panels F and H to <xref ref-type="fig" rid="fig2">Figure 2</xref>, which show that hPros1 is able to activate Tyro3 and Mer but not Axl. The ‘some activation’ of Axl by Pros1 mentioned by Reviewer 2 reflects lower molecular weight bands that are seen specifically in α-pY blots for Axl-expressing MEFs only when Axl is <italic>not</italic> activated by exogenous Gas6 – they consistently disappear when Axl is activated, and they do not increase in intensity with increasing concentrations of either rmPros1 or hPros1. (See <xref ref-type="fig" rid="fig2">Figure 2</xref> panel D, lane 8; panel E, lanes 1 and 8-11; and panel F, lanes 8-14.) We have clarified the nature of these bands (which may reflect a low basal level of phosphorylation due to MEF production of endogenous Gas6) in the legend to the revised <xref ref-type="fig" rid="fig2">Figure 2</xref>. These new data are consistent with our original data, and clearly demonstrate that neither hPros1 nor rmPros1 can activate Axl. They are also consistent with the in-press work of Tsou <italic>et al.</italic> (<italic>J. Biol. Chem</italic>., in press, pii: jbc.M114.569020) cited above, in which mouse Pros1 was found to be able to activate STAT1 phosphorylation downstream of hybrid receptors composed of the ectodomain of either Tyro3 or Mer linked to the cytoplasmic domain of the R1 chain of the IFN-γ receptor, but <italic>not</italic> to activate a similar hybrid receptor containing the Axl ectodomain. This is now discussed in the Results section.</p><p>Finally, in our in-press <italic>Nature Immunology</italic> paper, we show that phagocytosis of apoptotic cells by macrophages that exclusively express Mer can be stimulated by both Gas6 and Protein S, whereas phagocytosis in macrophages that express exclusively Axl can only be stimulated by Gas6. In concert, all of this new work overwhelmingly argues that Axl is activated by Gas6 but not by Protein S.</p><p><italic>4) One has to wonder how physiologically significant is the difference between Axl and the other TAMs in terms of Gla domain dependence</italic>. <italic>Whereas Gla-less Gas6 seems to lose efficacy for Axl, removal of the Gla domain still reduces potency perhaps 20-50 fold for Mer and Tyro3. It would be helpful for the authors to put this into physiological context. What is the functional difference between 'dead' and 20-50 fold impaired for Gas6? Is there any?</italic></p><p>This is an interesting possibility, but one that we can’t address definitively.</p><p>It is indeed possible that a 20-50-fold reduction in potency might mean that the Gla-less Gas6 is effectively inert as a Tyro3 or Mer ligand <italic>in vivo</italic>, but this will depend on local ligand concentration, clustering, and other variables. However, the key point we want to make is that in this assay system, there is clearly a difference between Tyro3/Mer and Axl – this time in terms of the ability of Glaless Gas6 to activate them.</p><p>With respect to the inability of Gla-less Gas6 to activate Axl, we have also added a new set of <italic>in vivo</italic> experiments and a new <xref ref-type="fig" rid="fig5">Figure 5</xref> to the revised paper. We believe that these new experiments extend the findings of <xref ref-type="fig" rid="fig3">Figure 3B and E</xref> and <xref ref-type="fig" rid="fig4">Figure 4</xref> in a very powerful way. We injected (intravenously) either full-length or Gla-less recombinant mouse Gas6 into <italic>Gas6-/-</italic> mice, and then monitored the co-localization of the injected proteins with red pulp macrophages in the spleen 30 minutes after injection. (These macrophages are Axl-expressing.) We found that IV-injected full-length and Gla-less Gas6 bound equally well to these cells.</p><p>However, when we examined Axl activation (tyrosine phosphorylation) in these same macrophages, we found that the full-length ligand induced strong activation, while the Gla-less Gas6 produced no Axl activation at all – equivalent to an injection of saline. We assume that the PtdSer required for Axl activation by full-length injected Gas6 comes from the blood, which is full of PtdSer-displaying microparticles (derived from platelets, erythrocytes, leukocytes, and endothelial cells). These dramatic new results are presented in the Results section of the revised paper.</p><p><italic>5) Was cell surface expression of ECDTIgITKA confirmed</italic>, <italic>to exclude the trivial possibility that it is not accessible to hPros1 in</italic> <xref ref-type="fig" rid="fig5"><italic>Figure 5D</italic></xref><italic>?</italic></p><p>Yes – surface expression was confirmed. We have added a figure supplement to <xref ref-type="fig" rid="fig6">Figure 6</xref> to document this.</p><p>Reviewer 3 major comments:</p><p><italic>[…] This reviewer sees two major concerns regarding experimental design used in this study:</italic></p><p><italic>1) The authors used human protein S in studies investigating the mechanisms of signaling in murine TAM receptors (</italic><xref ref-type="fig" rid="fig2 fig5 fig6"><italic>Figures 2C F, 5D, and 6B</italic></xref><italic>). Because the activity and specificity of protein S and Gas6 could be species-specific (ref. Hafizi and Darlback, FEBS J., 2006), it is not clear whether all the data acquired with human protein S are applicable to the signaling mechanisms of murine protein S. In addition, preparation of human protein S differed from that of murine protein S and Gas6; human protein S was purified from human serum, and both murine and human protein S were generated as His-tag-conjugated recombinant proteins. Therefore, comparison of human protein S and murine Gas6 abilities to induce signaling can be influenced by many factors, including purification methods, presence of tag sequence, and efficiency and types of post-translational modifications</italic>.</p><p><italic>Because the data that compare signaling activity and specificity of murine protein S and Gas6 are very important to properly interpret the mouse in vivo data, most of the in vitro experiments investigating signaling mechanisms of protein S should be performed using murine protein S</italic>.</p><p>As indicated above (please see our response to Reviewer 2, point 3), we have now included additional data with recombinant mouse Protein S in revised <xref ref-type="fig" rid="fig2">Figure 2</xref> and its supplement (five new panels in all). It is also important to emphasize that the genetic studies we present in the retina (revised <xref ref-type="fig" rid="fig7">Figure 7</xref>), together with those we have previously published in Burstyn-Cohen et al., <italic>Neuron</italic> 76: 1123-32 (2012), unambiguously demonstrate that mouse Protein S functions as a ligand for mouse Mer.</p><p><italic>2) The authors claim that PtdSer exposed on a small fraction of cultured cells binds to the Gla domain of protein S and Gas6, and this binding is necessary for optimal signaling via TAM receptors. To clearly show that PtdSer exposed on minor cell populations plays a critical role in Gas6/protein S signaling, it will be necessary to demonstrate that induction of PtdSer exposure and elimination of exposed PtdSer on cells affect the magnitude of signaling by protein S/Gas6</italic>.</p><p>As discussed above, we have addressed this point in multiple ways. We show that a Gas6 variant that lacks its Gla domain and cannot bind PtdSer binds to Axl with wild-type affinity but is incapable of activating the receptor either in vitro or <italic>in vivo</italic> (<xref ref-type="fig" rid="fig3 fig4">Figure 3, 4</xref> and the new <xref ref-type="fig" rid="fig5">Figure 5</xref>). We have shown that the inclusion of PtdSer-containing membranes, from either apoptotic cells or enveloped viruses, shifts the ligand dose-response activation profiles for both Axl and Mer to lower ligand concentrations (Bhattacharyya et al. <italic>Cell Host &amp; Microbe</italic> 14: 136-47 (2013); Zagórska et al., <italic>Nature Immunology</italic>, in press (October 2014), discussed in the Results section). We show that blocking PtdSer with annexin V inhibits Tyro3 activation (<xref ref-type="fig" rid="fig4">Figure 4A</xref>) and that depletion of calcium ions that are required for PtdSer-Gla domain interaction inhibits Axl activation but not binding by full-length Gas6 (<xref ref-type="fig" rid="fig4">Figure 4C, E</xref>). The phagocytosis of apoptotic germ cells by Sertoli cells in the testis and of outer segment membranes by RPE cells in the retina – the two systems we analyze genetically in our paper – have both been previously shown to be entirely dependent on the exposure of PtdSer, and in the case of the retina this exposure cycles during the day and is light-induced (Ruggiero et al., <italic>PNAS</italic> 109: 8145-8 (2012)). This is now discussed in the Discussion section.</p></body></sub-article></article>